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Abstract
Medication use and gait impairment are two of the most important risk factors for falls.
Several drug classes have been classified as fall risk-increasing drugs (FRIDs). Gait is an
important marker of overall health and independence in older adults. The overall aim of
this thesis was to examine the relationship between FRIDs and gait performance in older
adults through two studies. Firstly, our systematic review of twenty studies on the
association between FRIDs and gait performance found that the use of drugs with
sedative properties is associated with reduced gait speed. Secondly, we conducted a
cross-sectional analysis of data from the Gait and Brain Study. We found that among
community-dwelling older adults aged 65 years old and over, diuretic use was associated
with significantly reduced gait speed and statin use was associated with significantly
increased stride time variability. Future longitudinal studies are required to determine the
clinical relevance of our findings.
Keywords: gait, falls, older adults, psychotropic drugs, cardiovascular drugs
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Summary for Lay Audience
Falls in older adults are a major public health concern in older adults. Medication use and
gait (walking) impairment are two of the most important risk factors for falls. Several
drug classes have been identified as fall risk-increasing drugs. Gait is also an important
marker of overall health and independence in older adults therefore the aim of this thesis
was to examine the relationship between fall risk-increasing drugs and gait performance
in older adults through two studies. Our first study was a systematic review of the current
published evidence on the relationship between fall risk-increasing drugs and gait. We
found that using drugs with sedative properties is associated with reduced gait speed in
older adults. Our second study analyzed data collected from the Gait and Brain Study
which is a study of community-dwelling older adults aged 65 years old and over living in
London, Ontario. We found that the use of diuretics was associated with significantly
reduced gait speed and that statin use was associated with significantly increased stride
time variability which is a marker of gait (walking) instability and a predictor of future
falls. Future studies following up patients over a period of time are needed to determine
the relevance of our findings in a clinical setting.
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Chapter 1
1 Introduction
This chapter introduces three concepts: falls, fall risk-increasing drugs and gait. It starts
with an overview of falls and their risk factors including a more detailed discussion of
fall risk-increasing drugs. The chapter ends with a detailed discussion of gait including
the gait cycle, gait assessment methods and the two gait parameters examined in this
thesis: gait speed and gait variability.

1.1 Epidemiology of Falls
In 2018, falls were the second leading cause of death due to accidental or unintentional
injury worldwide with an estimated 646,000 fatal falls taking place each year1. Falls
disproportionately affect older adults. In Canada, an estimated 20% to 30% of adults 65
years old and over suffer at least one fall each year and half of those 80 years old and
over experience a fall each year2. Falls are associated with a range of negative physical
and mental health outcomes. Injury and fractures are major consequences of falls. Falls
account for 80% to 85% of injury-related hospitalizations and 95% of hip fractures
among older adults in Canada2,3. One third of Canadian older adults treated for fallrelated injury are discharged into long-term care2. In addition, falls are also associated
with several psychological consequences including fear of falling, avoidance of activity,
anxiety and depression4-7. Falls are also associated with a significant economic cost. Fallrelated costs per capita were almost four times higher for Canadian seniors compared to
Canadians under the age of 642. The aging of the population means that falls are going to
become a more pressing health, social and economic challenge in future.

1.2 Risk Factors for Falls
Falls are multifactorial. The risk of falls increases with the number of risk factors. It was
shown that among community-dwelling older adults, fall risk increases from 8% when no
risk factors are present to 78% in the presence of four or more risk factors8. Fall risk

1

factors can be divided into intrinsic factors (such as aging, comorbidities, visual and
auditory deficits, balance and gait problems, etc.) and extrinsic factors (such as tripping
and slipping hazards, improper usage of assistive devices, etc.). It is thought that many
falls result from interactions among different risk factors rather than from simple additive
effects9,10. An example relevant to this thesis would be comorbidities that cause sensory
impairment. These comorbidities result in medications being prescribed, which affect
balance and gait, which increases fall risk over that posed by the comorbidities alone.
Fall-increasing risk factors were further categorized by the World Health Organization
(WHO) into biological, behavioral, environmental and socioeconomic domains11. Two of
the most important risk factors for falls are medication use and impaired gait
performance, which form the core of this thesis.

1.3 Fall Risk-Increasing Drugs (FRIDs)
Medications that are associated with increased fall risk are collectively known as fall
risk-increasing drugs (FRIDs). Due to the prevalence of polypharmacy in older adults, the
use of FRIDs is common. Older adults are also at risk of prescribing cascades12. A
prescribing cascade occurs when an adverse drug reaction is misinterpreted as a new
medical condition and results in the prescription of additional drugs which may include
FRIDs. While no universal evidence-based list of FRIDs has been developed to date,
psychotropic and cardiovascular drugs have been identified as the most important FRID
classes13.
The association between these psychotropic drugs and increased fall risk in older adults
has been well-established by several systematic reviews and meta-analyses14-17. Beers
criteria for potentially inappropriate medication in older adults recommends against the
use of antipsychotics, antidepressants, benzodiazepines, hypnotics and sedatives in
geriatric patients with a history of falls18. The evidence for cardiovascular drugs is more
mixed. Loop diuretics have been shown to be associated with falls while inconsistent
associations have been reported for antihypertensives, beta-blockers and
antiarrhythmics16,17,19,20.
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The mechanism of the associations between several FRIDs and increased fall risk is not
well understood given the multifactorial nature of fall risk and the involvement of
different bodily systems in mobility. Broadly, older adults experience age-associated
pharmacokinetic changes including slower metabolism and elimination of drugs as well
as increased permeability of the blood-brain barrier21. These changes may prolong or
augment the effect of medications. Several biological mechanisms for the association
between different FRIDs and fall risk have been suggested in the literature.
Antidepressants are thought to contribute to fall risk through sedation, impaired balance,
sleep disturbances and orthostatic hypotension22. Benzodiazepines have been linked to
falls through augmenting the inhibitory effect of GABA23 in the central nervous system
which in turn affects attention and alertness causing sedation. Cardiovascular drugs
including diuretics and various classes of antihypertensives are thought to increase fall
risk through orthostatic hypotension and syncope. However, these mechanisms have not
been extensively studied and are not well established. The body of evidence on the
biological mechanisms of the association between FRIDs and fall risk remains limited
particularly compared to the consensus on the link between FRIDs and fall incidence.

1.4 Gait
Gait is the medical term that describes walking in healthy adults. Gait is a complex
process that requires coordination among various bodily systems including the nervous,
sensory, respiratory, cardiovascular and musculoskeletal systems24. The normal gait
pattern is described by the gait cycle25 (Figure 1.1)

1.4.1 The Gait Cycle
In a normal gait pattern, the gait cycle represents the time interval between the first heel
strike of one foot and the next heel strike of the same foot26. The heel strike is the point at
which the foot strikes the ground and is also known as the initial contact. Only one foot is
considered in the gait cycle and is known as the reference foot. The gait cycle is
comprised of two major phases. The stance phase accounts for 60% to 65% of a normal
gait cycle and it represents the time interval between the first heel strike of the reference
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foot and the point at which the reference foot lifts off the ground. The swing phase
accounts for the remaining 40% to 35% of a normal gait cycle and it represents the time
interval between the reference lifting off the ground and coming into contact with the
ground once again26.

Figure 1.1 The Gait Cycle. Adapted from Montero-Odasso M. (2003)
The gait cycle can be analyzed through several spatial and temporal parameters. Gait
(walking) speed is the most commonly assessed gait parameter, and it is quantified by the
dividing the distance walked on a smooth surface by unit time. It is often expressed in
metres per second (m/s) or centimetres per second (cm/s). The significance of gait speed
as a marker of geriatric health is discussed in greater detail later in this chapter. Cadence
is a gait parameter that describes the number of steps walked per unit time and provides
information about the rhythm of walking27.
Other temporal parameters are often expressed in seconds and include stride time which
describes the time period between two footfalls of the same foot, step time which
describes the time period between the heel strike of one foot and the heel strike of the
opposite foot and double support time which describes the time in which both feet are in
contact with the ground27.
Commonly-measured spatial parameters of gait are often expressed in metres (Figure
1.2). These include stride length which is equivalent to one gait cycle and describes the
distance between two consecutive footfalls of the same foot. Step length describes the
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linear distance between the heel strike of one foot and the heel strike of the opposite foot.
Step width describes the distance between the midpoint of the footfall from one foot and
the midpoint of the footfall from the opposite foot27.

Figure 1.2 Spatial Gait Parameters. Adapted from Pradel G. et al. An Embedded Gait
Analysis System for CNS Injury Patients, Assistive and Rehabilitation Engineering
(2019)28

1.4.2 Gait Assessment Methods
Two main methods of gait assessment are observational and instrumental. Observational
assessments involve a visual examination of an individual’s gait pattern using clinical
judgement and expertise29. These examinations may be supplemented by tests such as the
Timed Up and Go Test (TUG), the Tinetti Performance-Oriented Mobility Assessment
(POMA) and the Timed-25 Foot Walk (T25-FW) which capture basic gait parameters
such as gait speed and cadence. Instrumental gait assessment methods are more objective
and capture several spatiotemporal gait parameters. These instruments include 3D image
processing techniques using cameras or wireless sensors, as well as instrumented mats
and walkways. One frequently used instrument is the GAITRite system which consists
of a portable walkway with embedded pressure sensors and software that calculates
spatiotemporal gait parameters for every footfall based on information transmitted from
the sensors30
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1.4.3 Gait Speed
Gait speed refers to the speed of walking over a smooth surface at a ‘usual’ pace. While it
is a primarily a measure of physical function, gait speed was shown to be a robust
predictor of a range of health outcomes including disability, cognitive function,
hospitalization, institutionalization, cardiovascular mortality and all-cause mortality31.
Gait speed is also an important predictor of future falls. Several studies showed that
fallers exhibit slower gait speed compared to non-fallers32-34. Gait speed is a responsive
measure that is appropriate for use in a variety of settings including community, hospital
and long-term care settings as well as different populations including healthy and
diseased older adults. As a result of the predictive capacity and responsiveness of gait
speed, it was termed the 6th vital sign and gait speed assessment is increasingly
recommended as part of regular health status examinations31,35.

1.4.4 Gait Variability
Gait variability is an important quantitative measure of gait performance. Variability
refers to the stride-to-stride fluctuations in a walking pattern which are exhibited by older
adults as part of the normal aging process and are also manifested in neurodegenerative
diseases. It was found that disease-free healthy older adults exhibit stride to-stride
fluctuations similar to those exhibited by young children. High stride-to-stride
fluctuations are indicative of unstable gait36.
Variability is quantified by the coefficient of variation (CV) of quantitative gait
parameters (CV = standard deviation/mean × 100)36. The use of the CV over the
standard deviation (SD) has some advantages. SD measures can be affected by outliers in
the data. Additionally, the CV is a unitless measure and allows for comparisons between
variabilities of gait parameters that are measured in different units.
There is growing evidence that gait variability may be a more sensitive measure of gait
instability and thus a more robust predictor of fall risk than other commonly measured
gait parameters such as gait speed36,37. Among the different measures of gait variability,
stride time variability and swing time variability were found to be closely associated with
falls. Fallers were shown to exhibit higher fluctuations in stride time (higher stride time
6

variability) compared to non-fallers37 (Figure 1.3). Stride time variability was also found
to be most closely associated with the frailty syndrome38.

Figure 1.3 Stride time variability patterns in a 78-year old faller compared to an 84-year
old non-faller
Copyright © American Congress of Rehabilitation Medicine and the American Academy
of Physical Medicine and Rehabilitation from Hausdorff et al (2001) (License included in
Appendix 1A)
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Chapter 2
2 Rationale and Objectives
This chapter outlines the rationale for this thesis including the conceptual framework this
thesis is based upon. It also outlines the objectives of the thesis

2.1 Rationale
As stated in the previous chapter, the mechanisms of the association between FRIDs and
falls are not well understood. It was recently shown that a complex interplay exists
between polypharmacy, gait and falls in which the association between polypharmacy
and falls in older adults was shown to be partially mediated by gait impairments1. The
study only considered the total number of medications as an exposure and did not
evaluate the impact of individual drug classes on gait. It is plausible that a similar
interplay could exist between FRIDs, gait and falls in which gait performance could be an
intermediate variable on the causal pathway between FRIDs and falls (Figure 2.1).

Figure 2.1 The interplay between fall risk-increasing drugs (FRIDs), gait and falls. It is
plausible that gait performance could be an intermediate variable on the causal pathway
between FRIDs and falls.
In contrast to the body of evidence on the associations between FRIDs and falls as well as
gait performance and falls, several knowledge gaps exist when it comes to the
relationship between FRIDs and gait. No systematic review focusing on the relationship
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between FRIDs and gait performance in community-dwelling older adults has been
published to date. Further, the relationship between FRIDs and quantitative gait
parameters other than gait speed is understudied. It is important to understand the
relationship between FRIDs and parameters such as gait variability which was shown to
be associated with increased fall risk and frailty in older adults. In order to address those
knowledge gaps, this thesis aims to review the existing evidence on the relationship
between psychotropic and cardiovascular FRIDs and investigate the association between
these medications and gait performance in a cohort of community-dwelling older adults.
The objectives of the thesis are discussed below.

2.2 Objectives
1. To systematically review the published evidence on the association between
psychotropic and cardiovascular FRIDs and gait performance in community-dwelling
older adults
2. To estimate the cross-sectional association between FRIDs and gait speed in
community-dwelling older adults using data from the Gait and Brain Study.
3. To estimate the cross-sectional association between FRIDs and gait variability
(quantified by stride time variability) in community-dwelling older adults using data from
the Gait and Brain Study.

2.3 References
1.

Montero-Odasso M, Sarquis-Adamson Y, Song HY, Bray NW, Pieruccini-Faria F,
Speechley M. Polypharmacy, gait performance, and falls in community-dwelling
older adults. Results from the gait and brain study. J Am Geriatr Soc.
2019;67(6):1182-1188. doi:10.1111/jgs.15774
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Chapter 3
3 Fall Risk-Increasing Drugs and Gait Performance in
Community-Dwelling Older Adults: A Systematic Review
3.1 Introduction
Falls are a major public health concern. Falls were the second leading cause of accidental
or unintentional injury deaths in 2018 worldwide1. In Canada, one third of adults aged 65
years old and over experience at least one fall each year. Falls account for 80% of injuryrelated hospitalizations among Canadian older adults2. In addition, falls are associated
with a range of other negative outcomes including fractures, early transition into longterm care, fear of falling, depression and anxiety2-5. The economic cost of falls is
substantial, both in terms of health system expenditure as well productivity loss; this will
become more pressing with the aging of the population2.
Medication use is one of the main risk factors for falls. Several psychotropic and
cardiovascular drugs have been identified as fall risk-increasing drugs (FRIDs). The
association between psychotropic drugs and increased fall risk is well-established6-9. The
evidence on the association between cardiovascular drugs and falls is more mixed;
however, associations between the use of diuretics, antihypertensive and antiarrhythmic
drugs and falls have been reported in the literature6,10,11.
The potential underlying mechanisms linking medications with increased fall risk remain
unclear. This is due to the large number of prescription drugs, the possibility for drugdrug interactions, and the potential for bias posed by confounding by indication. This is
made more complex by the highly multifactorial nature of falling. For these reasons,
studying an intermediate variable on the causal pathway such as gait performance may
help elucidate the means by which medications increase fall risk.
Gait is a complex process that involves coordination between the nervous, sensory,
cardiorespiratory and musculoskeletal systems15. Quantitative gait performance measures
including gait speed and gait variability have been shown to be robust predictors of fall
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risk12-14. It is plausible, therefore, that FRIDs may increase fall risk by causing gait
impairments.
Despite the large body of research on the association between FRIDs and falls, no
systematic review has yet examined the evidence on the effect of FRIDs on gait
performance in community-dwelling older adults. A previous literature review from 2013
examined the evidence on the association between FRIDs and postural control in both
young and older subjects. It captured only two studies that analyzed gait performance16.
Therefore, the aim of this systematic review is to evaluate the most up-to-date evidence
on the association between FRIDs and quantitative gait performance measures in
community-dwelling older adults.

3.2 Methods
The protocol for this systematic review was pre-registered with the PROSPERO –
International Prospective Register of Systematic Reviews (ID: CRD42020193949) after
the search but prior to study screening. We followed the PRISMA reporting guidelines
for systematic reviews17.

3.2.1 Identification of Studies
Two separate systematic searches were performed in Medline, Embase, PsycINFO and
CINAHL. The first search contained the following key concepts: “Gait”, “Psychotropic
drug” and “Older adult”. The concept “psychotropic drug” included all psychotropic drug
classes identified as potentially fall risk-increasing in the 2019 Beers Criteria for
Potentially Inappropriate Medication in Older Adults and by the European Geriatric
Medicine Society’s (EuGMS) Task Force on Falls18,19.
The second search contained the following key concepts: “Gait”, “Cardiovascular drug”
and “Older adult”. The concept “Cardiovascular drug” included all cardiovascular drug
classes identified as potentially fall risk-increasing by the EuGMS Task Force on Falls19.
A customized search strategy was created for each database including keywords and
MeSH terms. Additional studies were identified by searching grey literature in the Web
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of Science Core Collection and the ProQuest Global Theses and Dissertations Database.
The reference lists of included articles were checked to identify any missing studies. No
date restrictions were applied in any of our searches. We restricted our search to English
language studies. The psychotropic search was performed in January 2020 and updated
in June 2020. The cardiovascular search was performed in June 2020. The full search
strategy is provided in Appendices 3A and 3B for psychotropic FRIDs and cardiovascular
FRIDs respectively.

3.2.2 Study Selection
One author (A.O.) screened all titles and abstracts. After this initial screening, two
authors (A.O. and N.K.) independently screened full texts. Disagreements were resolved
by discussion and a senior author (M.S. or M.M.O.) was consulted when necessary. We
included RCTs, observational studies including cohort, case-control, cross-sectional and
case-crossover studies that investigated the association between medication use and gait
performance. Gait performance was defined as any quantitative gait performance
parameter which included the following: gait speed, any measure of gait variability, step
time, step width, step length, stride time, stride width, stride length, double support time
or cadence.
We included studies with community-dwelling participants who were all aged 60 years
and older or in which the mean age of participants was 60 years and older. Studies were
excluded if participants had neurodegenerative or neurological diseases that impair
mobility. We also excluded studies in which participants were hospitalized or
institutionalized as well as studies that assessed falls, balance or postural control without
assessing gait performance. Conference abstracts, case reports/case studies, case series,
systematic reviews and meta-analyses were also excluded. In the case of different studies
using the same cohort, the study with the larger sample size was included.

3.2.3 Quality and Risk of Bias Assessments
Study quality was assessed using the Newcastle-Ottawa Scale (NOS) for observational
studies20. The NOS scale was chosen because it assesses several criteria in three domains:

16

selection, comparability and outcome and it has been used in previous systematic reviews
on related topics such as the association between FRIDs and falls which made it easily
adapted to this review. A copy of the adjusted scale is provided in Appendix 3C. Each
study was given a score between 0 and 9. Studies with a score of 0-3 were considered
“low” quality, 4-6 “intermediate” quality and 7 or above “high” quality. In addition, risk
of bias assessments were conducted for RCTs included in our review using the Cochrane
risk-of-bias tool for randomized trials21. Quality assessment and risk of bias assessments
were performed independently by two reviewers (A.O. and N.K.). Disagreements were
resolved by discussion with the involvement of a senior author (M.S. or M.M.O.) when
necessary. Quality and risk of bias assessment results for all studies are provided in the
Appendix.

3.2.4 Data Extraction
The following information was extracted from each included study: author, year of
publication, study design, country, cohort used, participant characteristics (number of
participants, sex and mean age), medication class, gait assessment protocol, quantitative
gait performance measures assessed and effect size for each quantitative gait performance
measure assessed. Data extraction was performed by the primary author (A.O.) and
verified by a second reviewer (N.K.)

3.2.5 Data Synthesis
Study characteristics and findings were summarized using a descriptive approach broken
down by drug class. In cases where studies provided both unadjusted and adjusted effect
estimates, adjusted estimates were reported in the evidence table and qualitative
synthesis. A meta-analysis was not conducted due to the considerable heterogeneity in
gait assessment protocols (e.g. distance walked, usual vs. fast pace) as well as different
statistical effect measures reported (e.g .regression coefficients, mean differences, etc.)
In addition, there was an insufficient number of studies for most drug classes considered
to conduct a meta-analysis for each drug class.
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3.3 Results
Our first search was conducted to identify studies assessing the association between
psychotropic FRIDs and gait performance. This search identified 3187 studies. After
removal of duplicates and title and abstract screening, 32 studies underwent full-text
screening for eligibility. Twelve studies met the final inclusion criteria (Figure 3.1). Our
second search was conducted to identify studies assessing the association between
cardiovascular FRIDs and gait performance. This search identified 5568 studies. After
removal of duplicates and title and abstract screening, 25 studies underwent full-text
screening for eligibility. Eight studies met the final inclusion criteria (Figure 3.2). In
total, 20 studies were included in our qualitative synthesis. The characteristics and
findings of studies included are outlined below and described in greater detail in table 3.1
for psychotropic FRIDs and table 3.2 for cardiovascular FRIDs.

3.3.1 Characteristics of Included Studies
3.3.1.1 Psychotropic FRIDs
Twelve studies assessed the association between a psychotropic drug class and gait
performance in community-dwelling older adults. Of those, eight were cross-sectional
studies, two were prospective cohort studies, one was an open-label trial and one was a
randomized-controlled crossover trial. Studies were performed in the United States (4),
France (4), Australia (2), Finland (1), France (1), Italy (1), Israel (1) and Japan (1).
Psychotropic drug classes assessed included sedatives (5), antidepressants (3),
benzodiazepines (3) and antipsychotics (1). Across the twelve studies, gait assessment
was conducted over varying distances ranging from 2 m to 10 m. Ten studies assessed
normal pace walking while two assessed fast pace walking. All studies assessed gait
speed as an outcome except for one study that assessed gait variability only. In addition
to gait speed, studies assessed additional quantitative gait performance measures
including stride length (3), cadence (3), step width (1), stride time (1) and double support
phase (1). Measures of gait variability were assessed in two studies. All studies assessed
single-task gait performance. In addition, one study assessed dual-task gait performance
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and one study assessed obstructed gait performance.

Quality assessment results for all included studies are provided in the Appendix. In
summary, two studies were rated as “high” quality, seven as “intermediate” quality and
one as “low” quality (Appendix 3D). One RCT included in our review (Draganich et al.)
was assessed to have an overall “low” risk of bias. One open-label trial included in our
review (Palecau et al.) was assessed to have an overall “high” risk of bias (Appendix 3F)

3.3.1.2 Cardiovascular FRIDs
Eight studies assessed the association between a cardiovascular drug class and gait
performance. Of those, four were prospective cohort studies, three were cross-sectional
studies and one was a RCT. Studies were performed in the United States (5), Japan (2)
and France (1)
Cardiovascular drug classes assessed included angiotensin-converting enzyme (ACE)
inhibitors (3), statins (3), calcium-channel blockers (1) and one study assessed both ACE
inhibitors and statins (1). Across the eight studies, gait assessment was conducted over
varying distances ranging from 4 m to 20 m. All studies assessed normal pace walking
and one study also assessed fast pace walking. All studies assessed gait speed as an
outcome. In addition to gait speed, only one study assessed additional quantitative
measures of gait performance including stride length, swing time and gait variability. All
studies assessed single-task gait performance and none assessed dual-task performance.
Quality assessment results for all included studies are provided in the appendix. In
summary, five studies were rated as “high” quality and two were rated as “intermediate”
quality (Appendix 3E). One RCT included (Cesari et al.) was assessed to have an overall
“unclear” risk of bias (Appendix 3F)
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Identification

Figure 3.1 PRISMA flowchart for study selection (Psychotropic FRIDs)

Records identified
through database
searching
(n = 3185)

Records identified through
grey literature searching
(n = 2)

Screening

Records uploaded
(n = 3187)

Eligibility

Records screened
(n = 2778)

Full-text articles screened
for eligibility
(n = 32)

Duplicates removed
(n = 409)

Records removed
(n=2746)

Full-text articles excluded
with reasons
(n=20)

Inclusion

Did not assess association
between medication and gait
performance (n=8)
Studies included in
qualitative synthesis
(n = 12)

Conference abstract (n=5)
Studies using the same
cohort. Study with the larger
sample size used (n=2)
Mean age less than 60 years
old (n=2)
Conference poster (n=1)
Duplicate study (n=1)
No exposure to psychotropic
drug (n=1)
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Screening

Identification

Figure 3.2 PRISMA flowchart for study selection (Cardiovascular FRIDs)

Records identified
through database
searching
(n = 5562)

Records identified through
grey literature searching
(n = 6)

Records uploaded
(n = 5568)

Duplicates removed
(n = 980)

Records screened
(n = 4588)

Records removed
(n =4563)

Full-text articles screened for
eligibility
(n = 25)

Full-text articles excluded
with reasons (n=17)

Studies included in qualitative
synthesis
(n = 8)

Did not assess association
between medication use
and gait performance
(n=8)
Conference abstract (n=3)
Studies using the same
cohort - Study with the
larger sample size used
(n=2)
Full text not found (n=1)
Case report (n=1)
Case series (n=1)
Sample not representative
of community-dwelling
older adults (n=1)
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3.3.2 Summary of Findings
3.3.2.1 Psychotropic FRIDs
Antidepressants
Four studies assessed the association between antidepressant use and gait performance. In
a crossover RCT, Draganich et al. assessed the impact of single doses of amitriptyline (a
tertiary-amine tricyclic antidepressant (TCA)), desipramine (a secondary-amine TCA)
and paroxetine (selective serotonin reuptake inhibitor (SSRI)) on unobstructed and
obstructed gait performance (n=12)22. Obstructed gait performance was assessed by
having participants step over obstacles. No significant associations were reported
between unobstructed gait performance measures and any of the three drugs. Compared
to placebo, amitriptyline significantly reduced obstructed gait speed by as much as 8%
and obstructed cadence by as much as 4.9%. No significant associations were reported
for either desipramine or paroxetine.
In a cross-sectional study with a large sample size (n=1998), Donoghue et al. found that
after adjustment for confounders, non-specific antidepressant use was associated with a
significant reduction in gait speed ( = -7.51 cm/s) and stride length ( = -6.78 cm)
during single-task walking23. Antidepressant use was also associated with significant
reductions in gait speed and stride length during dual-task walking. Notably, while
antidepressant use was associated with an increase in both stride length coefficient of
variation (CV) and stride time CV during single-task walking, it was associated with a
decline in both of those measures during dual-task walking; however none of those
associations were statistically significant after adjustment.
A cross-sectional study by Poujol et al. assessed the association between the use of
antidepressants or benzodiazepines on stride time CV only (n=179)24. The study found
that, after adjustment for confounders, antidepressant or benzodiazepine use was
associated with a significant increase in stride time CV which is a marker of gait
instability. However, it is important to note that the authors did not report separate
findings for antidepressants and benzodiazepines and analyzed a combined independent
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variable for the use of either drug classes. In addition, the authors acknowledged that
their cohort consisted of older adults who showed a greater interest in health issues than
the general population of older adults.
In contrast to those findings, an open-label label trial by Palecau et al. (n=19) found that
SSRI and serotonin-norepinephrine reuptake inhibitor (SNRI) antidepressant therapy in
older adults diagnosed with clinical depression was significantly associated with a 10%
increase in gait speed as well as a 9.8% increase in stride length25. The study also found
that antidepressant therapy significantly reduced stride time variability by 8% which
indicates improved gait performance.

Benzodiazepines
Three studies assessed the association between benzodiazepine use and gait performance.
In a prospective cohort study with a large sample (n=885), Gray et al. evaluated the
association between benzodiazepine use and physical function in community-dwelling
older women26. They found that after adjustment for confounders, benzodiazepine use
was associated with a significant decline in gait speed over four years of follow-up ( = 0.34 m/s). Although no specific figures were provided, the authors reported that they
found a dose-response relationship in which higher-than-recommended doses of
benzodiazepine were associated with greater declines in overall physical performance.
Gray et al. also found that overall physical performance declined significantly more
among long-term users of benzodiazepines than short-term users.
A cross-sectional study by Landi et al. found no significant association between
benzodiazepine use and gait speed after adjustment in community-dwelling adults aged
80 years and over in a small (n=31) study27. Similarly, another cross-sectional study by
Eto et al. (n=25) found no significant difference in mean gait speed between users and
non-users of benzodiazepines among regular attendees aged 65 years and older of a day
care service28. The study found that mean step length was 12% lower in benzodiazepine
users than non-users. It is worth noting, however, that this study did not adjust for any
confounding factors.
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Sedatives
Five studies assessed the association between sedative use and gait performance. A
prospective cohort study with a large (n=2172) sample by Hilmer et al. assessed the
association between Drug Burden Index (DBI) – a measure of overall exposure to
medications with anticholinergic and sedative properties – and physical performance in
community-dwelling older adults29. The study found that at baseline, DBI was
significantly associated with slower usual gait speed after adjustment. Greater DBI
remained associated with significantly slower gait speed after three and five years of
follow-up although the effect size was small ( = -0.01 m/s)
A recent cross-sectional study with a large (n=2087) sample by Lim et al. assessed the
association between sedative medication use and physical function in communitydwelling older men 30. They found that mean gait speed was significantly lower in
sedative users than non-users after adjustment for confounders, although the effect size
was modest (mean difference = -0.05 m/s).
Similarly, Gnjidic et al. assessed the association between DBI and physical function in
community-dwelling older men (n=1705)31. They found that the sedative component of
the DBI (DBS) was associated with significantly slower gait speed after adjustment for
confounders, with a modest effect size (Mean difference = -0.08 m/s).
Furthermore, a cross-sectional study by Taipale el al. (n=700) assessed the association
between sedative load – a three-level measure of the cumulative effect of taking multiple
drugs with sedative properties – and physical function in a cohort of community dwelling
older adults32. Notably, the study found consistently lower mean gait speed scores in
women than men across all sedative loads (0, 1 and 2). After adjustment for confounders,
participants with a sedative load of 1 or 2 had significantly lower mean gait speeds than
those with a sedative load of 0. There were no significant differences in mean gait speed
between those with sedative loads of 1 or 2.
Finally, a cross-sectional study by Cao et al. (n=932) assessed the association between
sedative use and physical function in community-dwelling older women33. In contrast to

24

the aforementioned studies, this study found no significant association between sedative
use and gait speed after adjustment for confounders.

Antipsychotics
No study assessed antipsychotics exclusively, although Landi et al. assessed gait
performance in a subgroup of participants who used antipsychotics only in their crosssectional study of the association between anticholinergic drugs and physical function27.
They found no significant association between antipsychotic use and gait speed after
adjustment for covariates although the sample size was small (n=11)
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Table 3.1 Characteristics of studies included (Psychotropic FRIDs)
Author
Study
(Year of
Design
Publication)

Participant
Characteristics

Drug Class

Gait
Assessment
Protocol

Quantitative
Gait
Performance
Measures

Summary of Findings

Draganich et
al. (2001)22

n=12
Mean age: 66.9
Country: United
States

Antidepressants:
Amitriptyline
(tertiary-amine
TCA)

Normal
walking pace
over 9.5-m
(Unobstructed)

Gait speed,
stride length
and cadence

Unobstructed gait measures
were unaffected by any of the
three antidepressants

Despiramine
(secondaryamine TCA)
Paroxetine
(SSRI)

Normal
walking pace
over 9.5-m
encountering
obstacles of 3
different
heights
(Obstructed)

Randomizedcontrolled
crossover
trial
Washout
period: 6
days

Paleacau et
al. (2007)25

Open-labelcontrolled
trial
Follow-up
period: 10
weeks

n=19
Mean age: 68.6
Clinically
depressed
Country: Israel

Antidepressants : Normal pace
SNRI
walking over 2(venlafaxine) : 2 m
participants
SSRIs (various) :
17 participants

Amitriptyline significantly
reduced obstructed gait speed
by 8.0% (P=0.028) and
cadence by 4.9% (P=0.012)

Gait speed,
stride length,
stride time,
stride time
variability

Antidepressant therapy
significantly increased gait
speed (pre-therapy: 1.02 m/s
post-therapy: 1.13 m/s.
P=0.033) and stride length
(pre-therapy: 1.12 m to post
therapy: 1.23 m. P=0.006). It
also significantly decreased
stride time variability (pre-
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therapy: 36 ms to post-therapy:
33 ms. P=0.036)
Donoghue et
al. (2015)23

Crosssectional

n=1998
Mean age: 68.2
Country: Ireland
Cohort: The Irish
Longitudinal
Study on Aging
(TILDA)

Antidepressants

Two normal
pace walks
over 4.88-m
GAITRite
walkway
followed by
two walks
under cognitive
dual-task
conditions

Gait speed,
stride length,
cadence, step
width, double
support phase,
stride length
CV and stride
time CV

Antidepressant use was
associated with a significant
decline in gait speed (= -7.51
cm/s, P=<0.001) and stride
length (= -6.78 cm, P<0.001)
during single-task walking.
Associations remained
significant in dual-task
walking

Poujol et al.
(2010)24

Crosssectional

n=179
Mean age: 71.7
County: France

Antidepressant
or
benzodiazepine

Unspecified

Gait
variability
(CV of stride
time)

Antidepressant or
benzodiazepine use was
significantly associated with
increased gait variability
(=1.56, P=0.002)

Eto et al.
(1998)28

Crosssectional

n=53
Age: 65 years old
and over
Country: Japan

Benzodiazepine

Fast pace
walking over
10-m

Gait speed,
step length
and cadence

Benzodiazepine users had a
significantly lower mean step
length (38.2 cm) than nonusers (41.4 cm) (P=0.04). No
adjustment for confounders
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Gray et al.
(2003)26

Prospective
cohort
Follow-up
period: 4
years

Landi et al.
(2007)27

Cao et al.
(2008)33

Crosssectional

Crosssectional

n=885 (women
only)
Mean age: 77.7
Country: United
States
Cohort:
Established
Populations for
Epidemiologic
Studies of the
Elderly (EPESE)

Benzodiazepine

Normal pace
walking over
2.4-m

Gait speed

Benzodiazepine use was
associated with a significant
decline in gait speed over 4
years (: -0.34 m/s) (P=0.002)

n=364
Mean age: 85.8
Country: Italy
Cohort: Study of
Aging and
Longevity in
Sirente
(ilSIRENTE)

Benzodiazepine
(n=31)

Normal pace
walking over
4-m

Gait speed

Mean gait speed was
unaffected by benzodiazepine
or antipsychotic drug use

Normal pace
walking over 4m.

Gait speed

No significant association was
observed between sedative and
gait speed

Antipsychotics
(n=11)

n=932 (women
Sedatives
only)
Median age: 78
Country: United
States
Cohort: Women’s
Health and Aging
Study I (WHASI)
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Gnijdic et al.
(2009)31

Crosssectional

n=1705 (men
only)
Mean age: 76.9
Country:
Australia
Cohort: Concord
Health and Aging
in Men Project
(CHAMP)

Sedatives

Normal pace
walking over 6m.

Gait speed

Sedative drug burden was
significantly associated with
reduced gait speed (P<0.01)

Hilmer et al.
(2009)29

Prospective

n=2172
Mean age: 73
Country: United
States
Cohort: Health,
Aging and Body
Composition
Study

Sedatives

Normal pace
walking over 4m.

Gait speed

Cumulative exposure to
sedative and anticholinergic
medications over five years
was significantly associated
with a decline in gait speed in
the sixth year of follow-up (
= -0.01 m/s) (P=0.004)

n=700
Mean age: 81.3
Country: Finland
Cohort: Geriatric
Multidisciplinary
Strategy for the
Good Care of the
Elderly (GeMS)

Sedatives

Fast pace
walking over
10-m

Gait speed

Exposure to higher sedative
load was associated with
slower gait speed (P=0.0003)

cohort
Follow-up
period: 5
years

Taipale et al.
(2012)32

Crosssectional
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Lim et al.
(2019)30

Crosssectional

n=2087
Mean age: 78.2
Country:
Australia
Cohort:
Australian
Longitudinal
Study of Aging
(ALSA)

Sedatives
(n=235)

Normal pace
walking over
2.4-m

Gait speed

Sedative drug users had a
significantly lower gait speed
compared to non-users (Mean
difference: -0.05 m/s,
P<0.0038)
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3.3.2.2 Cardiovascular FRIDs
Angiotensin-Converting Enzyme Inhibitors (ACEI)
Four studies assessed the association between angiotensin-converting enzyme inhibitors
(ACEI) and gait performance. A RCT by Cesari et al. assessed the effect of ACEI
administration on physical function in a cohort of older adults with a high cardiovascular
risk profile (n=257)34. After a 6-month long administration of the ACEI fosinopril, no
significant difference in mean gait speed was observed between the fosinopril and
placebo groups.
A prospective cohort study with a large sample size by Gray et al. (n=5777) assessed the
association between ACEI use and physical function in participants in communitydwelling older women35. After adjustment for confounders, no significant association was
found between ACEI use and gait speed at baseline or during follow-up. It is worth
noting however that ACEI use at baseline was significantly associated with reduced mean
grip strength which is a measure of frailty status.
A prospective cohort study by Onder et al. also evaluated the association between ACEI
use and physical function in a cohort of community-dwelling older women with
hypertension (n=641)36. They found that after adjustment and, mean 3-year decline in gait
speed was 87% lower in continuous than intermittent ACEI users, 89% lower than
continuous/intermittent users of other antihypertensives and 90% lower than never users
of any antihypertensive drugs. These findings were statistically significant.
A recent cross-sectional study by George and Verghese also assessed the association
between ACEI use and gait performance in a cohort of community-dwelling older adults
with hypertension (n=281)37. In contrast to the study by Onder et al., this study found that
ACEI use was associated with significantly reduced gait speed after adjustment for
confounders ( = -7.29 cm/s) . Further, the study also assessed additional quantitative
gait performance measures including stride length, stride time, stride length variability
and stride time variability. ACEI use was associated with significantly reduced stride
length after adjustment ( = -6.86 cm) . No significant associations were found between
ACEI use and the other gait performance measures assessed.
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Statin
Four studies assessed the association between statin use and gait performance. A
prospective cohort study with a large (n=5777) sample size by Gray et al. assessed the
association between ACEI use and physical function in community-dwelling older
women35. After adjustment for covariates, no significant association was found between
statin and gait speed at baseline or during the 5-year follow-up period. Similarly, another
prospective cohort study of community-dwelling older adults by Lo-Ciganic et al.
(n=2405) found no significant association between the use of any statin and gait speed
over 5-years of follow-up38. The authors did report, however, that the use of low-dose
statins was associated with slower gait speed decline over 5 years compared to non-use
after adjustment for confounders. The authors defined gait speed decline as a decrease of
0.1 m/s or greater in one-year. Further, a recent cross-sectional study by Kawai et al
(n=1022) found no significant association between statin use and gait speed in a cohort of
community dwelling-older adults39.
Finally, a prospective cohort study by Dumurgier et al. assessed the association between
statin use and the decline in fast walking gait speed in a cohort of community dwelling
older adults40. In contrast to the rest of the included studies, this study found that statin
use was associated with significantly slower gait speed decline over 10 years of followup after adjustment for a large number of relevant confounders. The authors did note
however that the clinical relevance of their findings was uncertain due to the modest
effect size observed ( = 0.67 m/s)

Calcium-channel blockers (CCB(
A cross-sectional study by Deguchi et al. assessed the association between polypharmacy
and gait speed in a cohort of older outpatients (n=31)41. This study also examined the
relationship between gait speed and prescription contents. It was found that mean gait
speed among CCB users was 19% lower than among non-users. No differences in mean
gait speed were found between users and non-users of other antihypertensives or other
vasodilators. It is important to note however the number of CCB users in the sample was
small (n=19).
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Table 3.2 Characteristics of studies included (Cardiovascular FRIDs)
Author
(Year of
Publication)

Study Design

Participant
Characteristics

Drug Class

Gait
Assessment
Protocol

Quantitative
Gait
Performance
Measures

Summary of
Findings

Onder at al.
(2002)36

Prospective
cohort
Follow-up
period: 3 years

n=641 (women
only)
Hypertensive
Mean age: 78.9
Country: United
States
Cohort: Women’s
Health and Aging
I (WHAS-I)

ACE
inhibitor
(ACEI)

Normal
walking pace
over 4-m

Gait speed

Mean 3-year decline in gait
speed was significantly lower
in continuous ACEI users (1.7 cm/s) than that of either
intermittent ACEI users (13.6 cm/s) (P=0.015) or never
users of any drug (-17.9
cm/s) (P=0.001)

Cesari et al.
(2009)34

Randomizedcontrolled
crossover trial
Follow-up
period: 6
months
Washout
period: 3
months

n=257
Mean age: 65.7
Country: United
States
Cohort: TRAIN
Study

ACEI

Normal
walking pace
over 4-m

Gait speed

No significant difference in
mean gait speed between
drug and placebo groups after
6 months of ACEI
administration.

Gray et al.
(2012)35

Prospective
cohort

n=5777 (women
only)
Mean age: 70
Follow-up
Country: United
period: 6 years
States

ACEI

Normal
walking pace
over 6-m

Gait speed

No significant differences in
mean gait speed between
users and non-users at
baseline. No difference in
mean annual change in gait

(Fosinopril)
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Cohort: Women’s
Health Initiative
(WHI)

speed between users and
non-users during follow up.
Statins

Normal
walking pace
over 6-m

Gait speed

No significant differences in
mean gait speed between
users and non-users at
baseline. No difference in
mean annual change in gait
speed between users and nonusers during follow up.

George and
Verghese
(2016)37

Crosssectional

n=281
Hypertensive
Mean age (users):
76
Mean age: (nonusers): 77.2
Country: United
States
Cohort: Central
Control of
Mobility in Aging
(CCMA) Study

ACEI

Normal
walking pace
over 20-ft
GAITRite
walkway

Gait speed, stride
length, swing
time, stride
length variability,
swing time
variability

ACEI use was associated
with significantly lower mean
gait speed (91.7 cm/s) than
non-use (97.3 cm/s)
(P=0.016). ACEI use was
also associated with
significantly lower stride
length (109.9 cm) than nonuse (114.4 cm) (P=0.006)

Dumurgier et
al. (2013)40

Prospective
cohort
Follow-up
period: 10
years

n=4009
Mean age: 73.4
Country: France
Cohort: The
Three-City Study

Statins

Normal
walking pace
over 6-m. Fast
walking pace
over 6-m

Gait speed

Statin use at baseline was
associated with a slower
decline in fast walking speed
over 10 years of follow-up
(=0.67 m/s, P= <0.001)
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Lo-Ciganic et
al. (2014)38

Prospective
cohort
Follow-up
period: 5 years

n=2405
Mean age: 74.6
Country: United
States
Cohort: Health,
Aging and Body
Composition
Study

Statins

Normal
walking pace
over 20-m

Gait speed

Statin use was not associated
with gait speed decline over
the follow-up period

Kawai et al.
(2018)39

Crosssectional

n=1022
Mean age: 73.4
Country: Japan

Statins

Normal
walking pace
over 6-m. Fast
walking pace
over 6-m

Gait speed

No significant association
was observed between statin
use and normal gait peace

Deugchi et al. Cross(2019)41
sectional

n=31
Mean age: 79
Country: Japan

Calcium
channelblockers

Normal
walking pace
over 5-m

Gait speed

Users of calcium channelblockers had a significantly
lower gait speed (0.93 m/s)
than non-users (1.15 m/s)
(P=0.02)
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3.4. Discussion
This systematic review investigated the current evidence on the association between
cardiovascular and psychotropic FRIDs and gait performance in community-dwelling
older adults. The drug classes examined were those identified as fall risk-increasing by
the Beers Criteria as well as the EuGMS Task Force on Falls18,19. A total of 20 studies
were included in this review: 12 assessed the association between psychotropic FRIDs
and gait performance, and eight assessed the association between cardiovascular FRIDs
and gait performance. Overall, our review suggests that the use of drugs with sedative
properties is associated with reduced gait speed in community-dwelling older adults, with
the interesting exception of one open-label pre-post study that found that antidepressant
therapy was associated with increased gait speed and stride length, and decreased stride
time variability among older adults with clinical depression.25 We also found that statin
use is not associated with impaired gait performance in community-dwelling older adults
across the included studies with the exception of a large cohort study that showed slower
declines in fast walking speed among those taking statins at baseline. The evidence on
other drug classes was mixed. Additionally, there was an insufficient number of studies
that assessed quantitative gait parameters other than gait speed to be able to draw
conclusions about the effects of these drugs on these specific aspects of gait that are
emerging as sensitive prognostic indicators of fall risk and other health outcomes. A
discussion of the review findings for each drug classes is provided below
Our review suggests that the use of drugs with sedative properties is associated with a
decline in gait speed in community-dwelling older adults. This association was reported
in four of the five studies included in our review that examined the association between
sedative use and gait performance. These findings are consistent with the known effects
of sedatives on psychomotor slowing. It is important to note that sedatives are a broad
drug class comprising several drugs with sedative properties, which could be assessed as
stand-alone exposures such as benzodiazepines, antidepressants and hypnotics among
others. In order to account for this, we observed that studies have used aggregate
measures of sedative exposure such as the drug burden index (DBI) and the sedative load
model. The DBI incorporates the usage of drugs with anticholinergic properties and those
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with sedative properties42. The sedative load model assigns a sedative rating to each drug
based on its own sedative properties. A cumulative sum of those sedative ratings then
produces the sedative load.43 Importantly, only one of the five included studies was
longitudinal which supports the need for more studies to establish causality between
sedative use and reduced gait speed over time. Additionally, given that one study found
that female sedative users had lower gait speeds than male users, further research is
required to confirm if sex differences exist in the impact of sedative use on physical
function. Our review also supports the need for research on the association between
sedative use and quantitative gait performance measures other than gait speed since none
of the included studies assessed those parameters. The increasing availability of
electronic walkways and accelerometer-based wearables should enable more studies of
these parameters than the first studies of gait speed which could be done using only a stop
watch and a measured course.
Three studies assessed the association between antidepressant use and gait performance
and only one of those had a large sample size. It is plausible that due to the now wellestablished association between antidepressant use and falls, physicians have become less
likely to prescribe antidepressants for older adults or are more likely to encourage older
adults to discontinue antidepressant use. Additionally, although there are several
subclasses of antidepressants, only one of three included studies that examined
antidepressant use reported separate results for different subclasses of antidepressants.
Donoghue et al. reported that non-specific antidepressant use was associated with
reduced gait speed and stride length during both single and dual-task walking23. In
contrast, Draganich et al. found that amitriptyline – a tertiary amine TCA – significantly
reduced obstructed gait speed and cadence while unobstructed gait was not affected by
TCAs or SSRIs22. This is consistent with evidence that TCAs may have a stronger effect
on psychomotor and cognitive function than SSRIs due to their greater sedating
properties44. Our review supports the need for further investigation into the differential
effects of subclasses of antidepressants on gait performance.
Our review also suggests that the presence of depression should be taken into account
when considering the impact of antidepressants on gait performance. The open-label trial
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by Palecau et al. showed that antidepressant use improved gait speed and gait variability
in community-dwelling older adults diagnosed with clinical depression25. Although the
study has a high risk of bias due to its open-label design, its findings are consistent with
evidence showing that depression is associated with gait impairment therefore depressed
older adults are likely to have lower baseline gait performance45. One interpretation of
this study is that any possible pharmacologic effects of antidepressant therapy on
slowing gait are more than offset by the effects of the drug on treating depression.
The evidence on the association between benzodiazepine use and gait performance was
inconclusive which was notable given that benzodiazepines have sedative properties and
share similar adverse effects on psychomotor functioning with tricyclic antidepressants.
This can be attributed to several factors. Similar to antidepressants, only three studies
examined the effect of benzodiazepine use on gait in older adults in our review. Of those,
only one assessed the effect of benzodiazepine use in a large cohort of communitydwelling older women26. The two remaining studies assessed the effect of benzodiazepine
use in small subgroups of benzodiazepine-only users from a larger cohort and a random
sample of patients in a day clinic respectively27,28. Additionally, the only study that found
an association between benzodiazepine use and gait was a longitudinal study. Our review
thus supports the need for well-designed longitudinal studies to produce more conclusive
evidence on the association between benzodiazepine use and gait performance. Similar to
antidepressants, there exist different subclasses of benzodiazepines. There is evidence
that long-acting benzodiazepines have a greater fall risk-increasing effect than shortacting ones thus there is a need for more research into the differential effects of
benzodiazepine subclasses on gait performance7.
Our review suggests that there is no association between statin use and gait speed decline
in community-dwelling older adults. Although Dumurgier et al. found that statin use at
baseline was associated with a slower reduction in gait speed over ten years of followup, the authors highlighted that the clinical relevance of their finding was uncertain40.
Additionally, de Vries et al. found in their meta-analysis that statin use had a protective
effect on fall risk in older adults10. These findings along with the findings herein are
remarkable given the known adverse effects of statin on muscle function and
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structure46,47. One potential explanation is that because of those potential adverse effects,
physicians are less likely to prescribe statins for frail older adults who are clearly at risk
of reduced physical function. Nonetheless, given the prevalence of statin use among older
adults in general, our review supports the need for research into the association between
statin use and quantitative gait parameters other than gait speed.
Our review highlights the conflicting evidence on the association between ACEI use and
gait performance in older adults. Particularly, the impact of ACEI use on gait in
hypertensive patients is of interest given that hypertension was shown to be associated
with impaired gait performance48,49. In a cross-sectional study, George and Verghese
found that ACEI use was associated with reduced gait speed among hypertensive
community-dwelling older adults37. In contrast, Onder et al. found in a longitudinal study
that ACEI use was associated with slower gait speed decline in hypertensive older
women over 3 years36. Given the difference between study designs, it is plausible that the
positive effect of ACEI in slowing gait speed decline in the longitudinal study can be
attributed to their therapeutic effect on hypertension over time. The two other included
studies in our review, one of which was a RCT, found no association between ACEI use
and gait performance34,35. Given this inconclusive evidence, our review supports the need
for further research in this area particularly through clinical trials in both hypertensive
and non-hypertensive older adults.

3.4.1 Strengths and Limitations
To the best of our knowledge, this is the first systematic review to focus specifically on
the association between FRIDs and gait performance in community-dwelling older
adults. We searched four databases as well as two sources of grey literature, without date
restrictions. Our review does have potential limitations. With respect to generalizability,
our findings are restricted to community-dwelling older adults without neurodegenerative
or neurological diseases. The effects of medications on gait is a relatively recently
emerging topic and there is a of lack of consensus on drug classes that are considered fall
risk-increasing. We relied on guidelines such as the Beers criteria as well as the EuGMS
position paper on FRIDs to identify drug classes for inclusion in our search strategy. As a
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result, studies of gait performance in drug classes that were not identified as FRIDs in
those guidelines were not included in our review. As stated earlier, a meta-analysis was
not possible due to the inconsistency in statistical effect measures, insufficient number of
studies for each drug class and heterogeneity in gait assessment protocols. The lack of
meta-analysis means that evidence of potential publication bias cannot be examined using
symmetrical funnel plots. Importantly, while the majority of observational studies
included in our review adjusted for known strong confounders, residual confounding and
confounding by indication cannot be ruled out. Several studies included in our review
also did not consider important pharmacologic factors such as dosage, duration of use and
medication adherence. Finally, the restriction of study selection to English language
studies means that potentially relevant non-English studies would have been missed.

3.5. Conclusion and Implications for Practice and Research
Our systematic review examined the current evidence on the association between
psychotropic and cardiovascular FRIDs and gait performance in community-dwelling
older adults. We found that the use of drugs with sedative properties is associated with
reduced gait speed in older adults. Due to the myriad of adverse events associated with
slowing gait in older adults , including falls and fracture, caution should be taken in
clinical settings when prescribing those medications to older patients. Our review also
shows that statin use is not associated with gait speed reduction in older adults, although
further research is needed to assess the impact of statin use on other quantitative gait
performance measures.
Importantly, our review also identified several knowledge gaps to be addressed in future
research. In contrast to the large body of evidence on the association between FRIDs and
falls in older adults, the current evidence on the association between FRIDs and gait
performance in older adults is limited and conflicting. This is particularly true for
cardiovascular FRIDs. With the exception of statins and ACEI, our review did not
identify studies that examined the impact of other cardiovascular FRIDs on gait
performance. This might be attributed to the current lack of consensus over which
cardiovascular drug classes qualify as FRIDs and to the fact that gait performance has not
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traditionally been considered as an outcome of interest in studies of cardiovascular drugs.
More broadly, there is a need for more longitudinal research on the association between
FRIDs and changes in gait performance. Longitudinal research is important not only to
establish temporality but also to discern the impact of factors such as long-term use and
medication adherence.
Our review also identified knowledge gaps in gait assessment. Only six studies included
in the review assessed quantitative gait parameters other than gait speed. This made it
difficult to draw any conclusions about the impact of FRIDs on gait parameters other than
gait speed for any of the drug classes assessed. These parameters are important indicators
of gait performance and provide information about rhythm and pace of gait. Additionally,
only two studies assessed gait performance under dual-task or obstructed conditions. Our
findings support the need for more research in those areas in order to produce more
conclusive evidence on the association between FRIDs and gait performance in older
adults which will in turn help elucidate the causal mechanisms linking FRIDs with
increased fall risk in older adults.
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Chapter 4
4 Fall Risk-Increasing Drugs and Gait Performance in
Community-Dwelling Older Adults: Results from the Gait and
Brain Study
4.1 Introduction
Falls in older adults are a major public health concern worldwide. Falls were the secondleading cause of death from unintentional injury in 20181. One-third of adults aged 65
years old and over fall at least once each year2. In addition, falls are associated with a
range of negative health outcomes including fractures, anxiety, depression, disability and
accelerated transition into long-term care as well as a significant economic cost2-6. Falls
will become a more urgent challenge with the aging of the population.
Prescription medication use is a major risk factors for falls. Several psychotropic and
cardiovascular drug classes have been identified as fall risk-increasing drugs (FRIDs) in
older adults7-9. Clinical guidelines such as the Beers criteria recommend against the use
of psychotropic drugs in older adults with a history of falls or fractures10.
Gait impairment is another major risk factor for falls in older adults. Gait performance
can be assessed through quantitative gait parameters that correspond to different phases
of the gait cycle. Gait speed, usually measured at usual walking pace over a measured
course, has been shown to be a robust predictor of future falls as well as several health
outcomes including cognitive function, disability, and mortality11,12. Gait variability is
another aspect of gait performance which quantifies stride-to-stride fluctuations in gait
parameters such as stride time and step width during walking. High gait variability is a
marker of gait instability and was shown to be associated with increased fall risk and the
frailty syndrome13,14. Gait control is a complex process that involves coordination
between different bodily systems including the nervous, cardiorespiratory and
musculoskeletal systems. It is therefore plausible that gait control is affected by FRID
use. Given that gait impairment could be an intermediate variable on a causal pathway
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between FRID use and increased fall risk, it is important to better understand the impact
of FRID use on gait performance.
There is a large body of existing evidence on the association between FRIDs and falls in
older adults, and a growing literature on the effects of gait performance on fall risk. By
contrast, evidence on the association between FRIDs and gait performance is limited. A
small number of previous studies have shown that the use of sedative drugs is associated
with reduced gait speed in community-dwelling older adults16-18. With the exception of
statins and angiotensin-converting enzyme inhibitors (ACE inhibitors), the evidence on
the association between cardiovascular FRIDs and gait performance in older adults is
scarce. In addition, there remains a knowledge gap on the impact of FRIDs on gait
parameters other than gait speed such as stride time variability.
The aim of this study was to evaluate the cross-sectional associations between FRID use
and gait performance measures including gait speed and stride time variability in
community-dwelling older adults using data from Gait and Brain Study.

4.2 Methods
4.2.1 Study Population and Data Collection
The study analyzed baseline data collected from participants enrolled in the Gait and
Brain Study, an ongoing prospective cohort study with up to 15 years of follow-up
designed to investigate whether gait impairments can predict falls, frailty, cognitive
impairment and progression to dementia. Study design and logistics have been described
in detail elsewhere19. After obtaining written consent, participants underwent
demographic, functional, neuropsychological and gait assessments at baseline. To be
included in the study, participants had to be community-dwelling older adults 65 years or
older and able to walk 10 m independently without a gait aid. Exclusion criteria included
lack of English proficiency, Parkinson’s disease or any neurological disorder with motor
deficits and active major depression. Ethics approval was obtained from the University of
Western Ontario Health Sciences Research Ethics Board. Data collection occurred
between July 2007 and June 2016.
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4.2.2 Gait Assessment
Gait performance was assessed using the GAITRite electronic walkway (GAITRite
system, 600 cm long and 64 cm wide; CIR Systems Inc, Franklin, NJ). Assessments were
based on a validated and standardized gait protocol. Start and endpoints were marked on
the floor 1 m from the start and end of the walkway to avoid recording the acceleration
and deceleration phases. Every participant performed a practice trial on the walkway
prior to the assessment. Gait variability was assessed in addition to gait speed. Gait
variability was measured as the coefficient of variation (CV) of stride time [Stride time
CV = (standard deviation of mean stride time/mean stride time) x 100]. Stride time CV
was chosen as a measure of gait variability because it was shown to be robust predictor of
falls13,14.

4.2.3 Medication Ascertainment
Medications taken by each participant at baseline were recorded using validated
questionnaires and verified using participants’ electronic medical records. For the
purposes of the Gait and Brain Study, the trade name of each medication was manually
looked up and classified by the study assessors under one of the following classes:
neuroleptics, antidepressants, benzodiazepines, alpha-blockers, beta-blockers,
vasodilators, diuretics, statin and aspirin.

4.2.4 Covariates
Factors that could potentially confound the association between drug use and gait
performance were identified based on clinical judgement and a review of the literature.
Data was collected at baseline on demographic variables including age, sex and years of
education. Body mass index (BMI) was calculated using self-reported weight and height.
Cognitive function was assessed using the Mini-Mental State Examination (MMSE). The
presence of depressive symptoms was assessed using the Geriatric Depression Scale
(GDS). Physical activity level was determined based on self-reported general activity. In
addition, presence of the following co-morbidities at baseline was ascertained through
self-report: osteoarthritis, osteoporosis, congestive heart failure (CHF), history of
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myocardial infarction, angina, atrial fibrillation, hypertension, lung disease, diabetes
mellitus, history of stroke, history of transient ischemic attack (TIA), vision impairment
and hearing impairment.

4.3 Statistical Analysis
The frequency of use for each drug class (percentage) was determined. Descriptive
statistics were generated using mean and standard deviation (SD) for continuous
variables and frequency (percentage) for categorical variables. Multiple linear regression
models were created to assess the association between each drug class and each of the
two gait performance outcomes, mean gait speed in cm/sec. and stride time CV [Stride
time CV = (standard deviation of mean stride time/mean stride time) x 100]. The drug
classes tested included antidepressants, benzodiazepines, beta-blockers, alpha-blockers,
vasodilators, diuretics, statin and aspirin. Each drug class was assessed separately. In
each model, age and sex interactions with the drug were tested. We did not run models
testing the association between neuroleptics and gait performance due to small cell size
(n=4). The stride time CV variable was log-transformed in order to satisfy the normality
assumption for the linear regression analysis. All statistical analyses were run using Stata
16.
Each crude (unadjusted) model was adjusted for age, sex, years of education, BMI,
MMSE score, GDS score, general activity level, and use of other FRIDs. In addition, to
minimize confounding by indication, a comorbidity propensity score was created for each
drug class using logistic regression. The propensity score model was created using the
drug class (exposure) as the dependent variable and the comorbidities associated with that
drug class as well as those associated with the gait variable (outcome) as independent
variables. The propensity score was then included as a covariate in the multiple linear
regression model testing the association between the drug class of interest and the gait
variable of interest. This adjusted for the conditional probability that the drug was used
given the presence of the specified comorbidities. Confounding by indication and
propensity scoring are discussed conceptually in greater detail in the following sections
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4.3.1 Confounding by Indication
Confounding by indication is a common source of bias in pharmaco-epidemiological
observational studies. It is defined as distortion of an association between an exposure
and an outcome the presence of an indication for the exposure which happens to be the
true cause of the outcome20. In a clinical context, it arises when the clinical indication for
a specific treatment also affects the outcome. More specifically, in our study,
confounding by indication arises due to the presence of comorbidities that are potentially
associated with impaired gait performance (Figure 4.1). Several of those comorbidities
could also be indications for FRIDs. For example, there is evidence that depression is
associated with impaired gait performance in older adults21. At the same time, depression
is also an indicator for antidepressant use. As a result, an association between
antidepressant use and an impaired gait performance measure (e.g. reduced gait speed)
could be distorted by the presence of depression.

Figure 4.1 The principle of confounding by indication. The figure shows the general
principle along with an example of how it arises in our study. A comorbidity that is a
clinical indication for a fall risk-increasing drug can distort an association between the
drug and the gait outcome.
Confounding by indication cannot be eliminated in observational studies because
treatment assignment is based on clinical indications rather than randomization however
it can be minimized in statistical analyses. In our study, we opted to use propensity score
adjustment to adjust for confounding by indication due to comorbidities.
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4.3.2 Comorbidity Propensity Scoring
Propensity scoring is commonly used to control for confounding variables in pharmacoepidemiological studies22,23. The propensity score was first defined by Rosenbaum and
Rubin as the conditional probability of assignment to a particular treatment given the
vector of observed covariates24.
𝑃𝑆(𝑋) = Pr(𝑍 = 1| 𝑋)
𝑃𝑆(𝐶𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑦) = Pr(𝐹𝑅𝐼𝐷 𝑢𝑠𝑒 = 1 | 𝐶𝑜𝑚𝑜𝑟𝑏𝑖𝑑𝑖𝑡𝑦)
Figure 4.2. The propensity score (PS). The top line illustrates the general propensity
score function. The bottom line illustrates the function in the context of the study. The
comorbidity propensity score is conditional probability of FRID use given the
comorbidities specified in the propensity score model.
In our study, we generated a “comorbidity propensity score” for each drug class of
interest. These scores were generated using logistic regression models in which the drug
class of interest was the dependent variable and the comorbidities were the independent
variables. In generating a propensity score model, Rubin recommended the inclusion of
variables that are strongly related to the outcome25. Similarly, Brookhart et al,
recommended the inclusion of variables that are related to the outcome regardless of
whether or not they were related to the exposure26.
Since different comorbidities were associated with gait speed and gait variability, we
generated two sets of comorbidity propensity score models. One for the association
between every FRID class and gait speed (Appendix 4A) and another for the association
between every FRID class and stride time variability (Appendix 4B). In generating our
comorbidity propensity score models, we included comorbidities that were associated
with either the a) the drug class of interest (exposure) or b) the gait variable of interest
(outcome). The models were generated using the PSCORE command in Stata (Figure
4.3). This command verifies that the balancing property of the propensity score model is
satisfied and provides a warning when it is not. We also calculated a c-statistic and
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conducted a Hosmer-Lemeshow good-of-fitness test to ensure model fit for each of the
comorbidity propensity score models we generated.

Figure 4.3 Estimation of comorbidity propensity score on Stata. The example shown here
is for antidepressants (SSRIs). The PSCORE command is used to generate a logistic
regression model using the drug as the dependent variable and comorbidities associated
with the drug or gait speed as independent variables.
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The comorbidity propensity score was then included as a covariate in the multiple linear
regression analysis testing the association between the drug class of interest and the gait
variable of interest. This adjusted for the conditional probability that the drug was used
given the presence of the specified comorbidities. For example, the comorbidity
propensity score for statin was included as a covariate in the linear regression model
testing the association between statin and gait speed. This adjusted for the conditional
probability that statin was used given the presence of comorbidities associated with either
statin or gait speed.

4.3.3 Sensitivity Analysis
Regression diagnostics were run to ensure model fit and that regression assumptions were
satisfied. 90% of participants in the study had complete data for the all the variables used
in our analysis. For our main analysis, we conducted a complete case analysis. To
account for potential bias due to missing data, multiple imputation was conducted and
regression models were re-run using imputed values. We used multiple imputation by
chained equations (MICE) on Stata 16. Sensitivity analysis results are shown in
Appendix 4C.

4.4 Results
4.4.1 Characteristics of the Study Population
Baseline characteristics of the study population are shown in table 4.1 A total of 345
participants were assessed (mean age: 72 years old, S.D.: 6.55). The prevalence of
polypharmacy (five or more medications) among the participants was 66%. The
prevalence of each comorbidity among the participants is shown in table 4.1. The most
common comorbidity was hypertension (45%). Frequency of FRID use is shown in table
4.2. Statin was the most commonly used drug class among study participants (41%)
followed by aspirin (31%) and vasodilators (22%).
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4.4.2 The Association between FRID Use and Gait Speed
In the crude model (model 1), statistically significant associations between FRID use and
reduced gait speed were found for SSRIs, aspirin, statin, beta-blockers and diuretics.
After adjustment for demographic confounders (age, sex and years of education) (model
2), these associations remained statistically significant for SSRIs, statin and diuretics. In
the fully adjusted model (model 3), only diuretic use was significantly associated with
reduced gait speed. Notably, after adjustment for confounders, there was an association
between vasodilator use and increased gait speed however this association was not
statistically significant. No statistically significant age or sex interactions were observed
for any of the drug classes thus those terms were dropped from the models. Full results
for the associations between FRID use and gait speed are shown in table 4.3

4.4.3 The Association between FRID Use and Stride Time
Variability (Stride Time CV)
In the crude model (model 1), statistically significant associations between FRID use and
increased stride time variability were found for statin and alpha-blockers. After
adjustment for demographic confounders (model 2), statin use was significantly
associated with increased stride time variability. This association remained statistically
significant in the fully adjusted model (model 3). No statistically significant age or sex
interactions were observed for any of the drug classes thus those terms were dropped
from the models. Full results for the associations between FRID use and stride time
variability are shown in table 4.4
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Table 4.1 Baseline Characteristics of the Study Population, n=345
Demographic characteristics
Age, mean (SD)

72.4 (6.6)

Years of education , mean (SD)

14.6 (3.2)

Female, n (%)

198 (58.6)

Health-status characteristics
Body Mass Index (BMI), mean (SD)

28.1 (5.4)

Mini-Mental State Examination (MMSE) score , mean
(SD)

27.5 (2.2)

Geriatric Depression Scale (GDS) score, mean (SD)

2.4 (2.7)

Number of falls within the past year, mean (SD)

0.6 (1.4)

Polypharmacy, n (%)

228 (66.1)

Suffered falls within the past year, n (%)

109 (32.3)

Fear of falling, n (%)

45 (13.4)

Smoking, n (%)

104 (31.3)

General activity level, n (%)
Vigorously Active

141 (42.0)

Moderately Active

144 (43.0)

Seldom Active

46 (13.0)

Comorbidities
Number of comorbidities , mean (SD)

5.1 (2.7)

Comorbidities, n (%)
Depression

88 (26.4)

Cardiac diseases

52 (15.4)

Myocardial infarction

20 (5.9)

Angina

19 (5.6)
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Hypertension

155 (45.9)

Lung disease

21 (6.2)

Stroke or Transient ischemic attack

35 (10.4)

Osteoarthritis

126 (37.3)

Osteoporosis

53 (15.7)

Diabetes milletus

51 (15.1)

Visual impairment

116 (34.3)

Hearing impairment

122 (36.1)

Cancer

78 (23.1)
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Table 4.2 Medication Use in the Study Population

Drug class

n (%)

Neuroleptics

4 (1.2)

Antidepressants

45 (13.3)

Benzodiazepines

20 (5.9)

Beta-blockers

55 (16.3)

Alpha-blockers

25 (7.4)

Vasodilators

73 (21.7)

Diuretics

62 (18.3)

Statin

139 (41.1)

Aspirin

104 (30.8)
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Table 4.3 The Associations between FRID use and Gait Speed (cm/s)
Model 1

Model 2

Model 3

Drug class

Coefficient (95% CI)
(cm/s)

P-value

Coefficient (95% CI)
(cm/s)

P-value

Coefficient (95% CI)
(cm/s)

P-value

Antidepressants

-10.06 (-16.91, -3.21)

0.004

-7.23 (-13.59, -0.87)

0.026

-1.90 (-8.68, 4.88)

0.582

Benzodiazepines

-2.93 (-12.91, 7.04)

0.563

-1.79 (-11.13, 7.56)

0.707

-1.29 (-10.21, 7.62)

0.776

-10.91 (-16.88, -4.94)

<0.001

-10.49 (-15.98, -5.00)

<0.001

-7.97 (-13.94, -2.00)

0.009

-9.50 (-14.18, -4.82)

<0.0001

-6.64 (-11.14, -2.14)

0.004

-1.47 (-6.23, 3.30)

0.546

Vasodilators

-2.20 (-7.93, 3.53)

0.45

0.27 (-5.02, 5.57)

0.919

4.83 (-0.66, 10.31)

0.084

Beta-blockers

-7.59 (-13.96, -1.21)

0.02

-5.82 (-11.77, 0.13)

0.055

-3.13 (-9.42, 3.16)

0.328

Alpha-blockers

-5.77 (-14.74, 3.21)

0.207

-3.29 (-11.93, 5.36)

0.455

-6.20 (-14.59, 2.20)

0.147

Aspirin

-5.34 (-10.41, -0.27)

0.039

-3.18 (-7.98, 1.62)

0.194

-0.14 (-4.96, 4.68)

0.954

Diuretics
Statin

Model 1 is unadjusted (crude)
Model 2 is adjusted for age, sex and years of education
Model 3 is adjusted for age, sex, years of education, Body Mass Index (BMI), Geriatric Depression Scale (GDS) score, Mini-Mental State
Examination (MMSE), general activity level, other FRID use and comorbidity propensity score.
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Table 4.4 The Associations between FRID Use and Stride Time Variability (Stride Time CV)
Model 1
Drug class

Model 2

Model 3

Coefficient (95% CI)

P-value

Coefficient (95% CI)

P-value

Coefficient (95% CI)

P-value

Antidepressants

0.11 (-0.03, 0.25)

0.127

0.09 (-0.05, 0.23)

0.221

0.01 (-0.15, 0.17)

0.905

Benzodiazepines

0.07 (-0.14, 0.27)

0.511

0.11 (-0.10, 0.31)

0.31

0.12 (-0.09, 0.32)

0.270

Diuretics

0.03 (-0.10, 0.15)

0.658

0.04 (-0.09, 0.16)

0.553

-0.05 (-0.18, 0.09)

0.515

Statin

0.16 (0.06, 0.26)

0.001

0.14 (0.04, 0.24)

0.004

0.13 (0.02, 0.24)

0.026

Vasodilators

0.04 (-0.08, 0.16)

0.504

0.01 (-0.10, 0.12)

0.861

-0.05 (-0.17, 0.08)

0.491

Beta-blockers

0.07 (-0.06, 0.21)

0.267

0.07 (-0.06 0.20)

0.27

0.09 (-0.05, 0.24)

0.209

Alpha-blockers

0.20 (0.02, 0.38)

0.034

0.16 (-0.03, 0.35)

0.096

0.15 (-0.05, 0.34)

0.144

Aspirin

0.07 (-0.04, 0.17)

0.21

0.04 (-0.06, 0.15)

0.447

-0.01 (-0.12, 0.11)

0.898

Model 1 is unadjusted (crude)
Model 2 is adjusted for age, sex and years of education
Model 3 is adjusted for age, sex, years of education, Body Mass Index (BMI), Geriatric Depression Scale (GDS) score, Mini-Mental State
Examination (MMSE), general activity level, other FRID use and comorbidity propensity score
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4.5 Discussion
In this cohort of 345 community-dwelling older adults, diuretic use was associated with
reduced gait speed and statin use was associated with increased stride time variability.
These associations remained statistically significantly after adjustment for covariates.
Although the associations were not statistically significant, we found that vasodilator use
was associated with increased gait speed and reduced stride time variability both of
which are markers of improved gait performance.
To the best of our knowledge, ours is the first study to report an association between
diuretic use and reduced gait speed in older adults. This association is consistent with
existing evidence on the association between diuretic use and increased fall risk.
Longitudinal research is required to establish whether this association between diuretic
use and reduced gait speed in older adults is causal. Loop diuretics have a greater
natriuretic effect than thiazide diuretics and they can generate hypovolemia therefore they
may have a greater fall risk-increasing effect. Future research should consider whether
loop diuretics would have a more detrimental effect on gait performance than thiazide
diuretics27. The biological mechanisms behind diuretic use and gait performance and
increased fall risk are not well understood. Besides the hypovolemic effect of loop
diuretics which can exacerbate postural blood pressure changes, thiazide diuretics can
cause hypokalemia and hyponatremia both of which were shown to be associated with
reduced alertness and increased fall risk28.
We found no statistically significant association between statin use and reduced gait
speed. This is consistent with several previous studies29,30,31. While one study found that
statin use was associated with a slower decline in fast-walking speed over 10 years of
follow-up, the authors noted that the clinical relevance of their finding was uncertain32. In
contrast, we found that statin use was associated with increased stride time variability
which is an indicator of gait instability and increased fall risk. Statin is associated with
adverse effects on muscle structure and function, including increased risk of myopathy,
which may explain this finding33,34. We did not find any published studies that
investigated the association between statin and gait variability measures therefore further
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research is needed to corroborate our findings and determine their clinical relevance. This
is particularly important given the high prevalence of statin use among older adults which
was also reflected in our study. Statin was the most commonly-used drug class in our
cohort (41% of participants in our study were statin users).
We found that after adjustment for demographic variables (age, sex and years of
education), vasodilator use was associated with increased gait speed. This association
was not statistically significant in the fully adjusted model. Similarly, vasodilator use was
associated with reduced stride time variability in the fully adjusted model. This
association was also not statistically significant and the effect size was relatively modest.
While those findings are non-significant, the associations between vasodilator use and
improved gait performance parameters are notable. There is conflicting evidence on the
impact of vasodilators such as angiotensin-converting enzyme inhibitors (ACE inhibitors)
on gait speed and physical function in older adults35-37. A previous study with a small
sample size (n=31) found that calcium-channel blockers users had a significantly lower
mean gait speed than non-users38. Given that confounding by indication cannot be ruled
out in observational studies, positive effects of vasodilators reported in previous studies
could still be attributed to their therapeutic effects on underlying conditions such as
hypertension which is a risk factor for impaired gait performance39,40. We recommend
further research into this question, preferably using randomized-controlled trials (RCTs),
and focusing on subclasses of vasodilators since this is a broad drug class.
We found no statistically significant associations between either beta-blocker or alphablocker use and gait performance. Our cohort had a relatively large number of aspirin
users (n=104) however we found no statistically significant associations between aspirin
and gait performance. The existing evidence on the association between those drug
classes and gait performance is scarce and further research is needed into this topic to
better understand the impact of those widely-used drug classes on gait performance in
older adults. Notably, a recent meta-analysis found that beta-blocker use had a protective
effect on falls which was attributed by the authors to the potential cardioprotective effect
of those drugs27.
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Remarkably, we also found no statistically significant associations between either
antidepressant use or benzodiazepine use and gait performance. It is worth noting that
when the multiple regression model for the association between benzodiazepine use and
gait speed was re-run after multiple imputation, the regression coefficient was positive as
opposed to negative in the complete case analysis. The association was not statistically
significant in either analysis. This is possibly explained by the small number of
benzodiazepine users in our study (n=20).
Antidepressant use was associated with reduced gait speed after adjustment for
demographic confounders but it did not remain significant in the fully adjusted model.
This is in contrast to the well-established association between antidepressant use and falls
as well as previous studies that reported an association between antidepressant use and
reduced gait performance in older adults41,42. Our results could potentially be explained
by the small number of antidepressant users in our cohort (n=45) and the fact they were
all users of SSRIs (selective serotonin reuptake inhibitors). There is evidence that SSRIs
may be less sedating than tricyclic antidepressants43. A previous RCT showed that the
SSRI paroxetine did not affect unobstructed or obstructed gait performance in healthy
older adults however the study also had a small sample size (n=12)44.
Strengths of our study include a large and well-characterized cohort of communitydwelling older adults who underwent instrumented in-person assessments of several gait
performance parameters by experienced staff. Importantly, our study helps to address a
knowledge gap in the literature on the association between cardiovascular FRIDs and gait
performance particularly on gait parameters other than gait speed. To the best of our
knowledge, ours is the first study to report an association between diuretic use and
reduced gait speed as well as between statin use and increased gait variability in
community-dwelling older adults. Our analyses controlled for strong known demographic
and health status confounders. We aimed to minimize confounding by indication by
adjusting for comorbidity using propensity scores. Propensity scoring is increasingly used
in pharmaco-epidemiological studies and there is evidence that it yields comparable
results to those obtained by including individual covariates in the regression model45,46.
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Our study is not free of limitations. Due to the cross-sectional design of the study, we
were unable to assess temporality of the associations. The clinical relevance of those
associations is also uncertain. We were unable to study subclasses of broader drug classes
such as vasodilators which limits our ability to draw more specific conclusions. We did
not consider the impact of pharmacological factors such as dosage, duration of use,
adherence to medication and drug-drug indications. Finally, although we aimed to
minimize confounding by indication by adjusting for propensity scores, confounding by
indication cannot be eliminated due to the observational nature of the study. Additionally
a limitation of propensity scoring is its inability to account for unmeasured confounders
which results in residual confounding bias.

4.6 Conclusion
In our cohort of community-dwelling older adults, diuretic use was associated with
reduced gait speed and statin use was associated with increased stride time variability.
Further longitudinal research is needed to establish the causality of those associations.
Given our finding and the existing evidence on the association between diuretic use and
falls in older adults, clinicians should use caution when prescribing these medications to
older adults.
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Chapter 5
5 Synthesis and Conclusion
This chapter synthesizes the findings of the two studies conducted in this thesis. It
provides a summary of the findings from both studies and outlines the contributions of
those findings to the existing knowledge body. Finally, this chapter notes some of the
limitations of this thesis and directions for future research identified by this thesis.

5.1 Summary of Studies
The main aim of this thesis was to contribute to the knowledge body on the relationship
between medication use and gait performance in older adults. This was achieved through
two studies. First, we conducted a systematic review of the existing evidence on the
association between psychotropic and cardiovascular fall risk-increasing drugs (FRIDs)
and gait performance in community-dwelling older adults (Chapter 3). This review
identified several knowledge gaps on the association between FRIDs and gait
performance. Second, we attempted to address those knowledge gaps through a crosssectional study of the association between FRID use and gait performance among
community-dwelling older adults using medication use data from the Gait and Brain
Study (Chapter 4). Specifically, we analyzed gait speed and stride time variability
(quantified as the coefficient of variation of stride time).
Our systematic review found that drugs with sedative properties are associated with a
decrease in gait speed among community-dwelling older adults. An exception to this was
an open-label trial that found that antidepressant therapy improved gait performance in
patients with clinical depression1. Our review also found that in all studies reviewed
except one, gait speed was not affected by statin use. The exception was a large cohort
study in which statin use reduced gait speed decline in older adults over 10 years of
follow-up; however the authors noted that the clinical relevance of this finding was
uncertain due to the modest effect size observed2. Our review identified several
knowledge gaps. With the exception of ACE inhibitors and statins, no studies assessed
the association between other cardiovascular drugs and gait performance in older adults.
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Additionally, there was an insufficient number of studies on the impact of FRIDs and gait
performance measures other than gait speed.
Our cross-sectional study found that among a cohort of community-dwelling older adults
(65 years old and over) living in London, Ontario,, after adjustment for covariates,
diuretic use was associated with reduced gait speed (B = -7.97 m/s, P= 0.009). We also
found that, after adjustment, statin use was associated with increased stride time
variability (B = 0.13, P=0.026). Notably, we also found that vasodilator use was
associated with increased gait speed and reduced stride time variability, both of which are
indicators of improved gait performance. However those associations were not
statistically significant after adjustment for covariates.

5.2 Contributions to Research
This thesis provides important contributions to the existing literature on the relationship
between medication use and gait performance. To the best of our knowledge, our
systematic review is the first review to focus specifically on the association between
FRIDs and gait performance in community-dwelling older adults. A previous literature
review conducted in 2013 examined the evidence on the relationship between FRIDs and
postural control, although it included both young and older adults3. Our study of the
association between medication use and gait performance in the Gait and Brain Study
addresses some of the knowledge gaps identified by our systematic review. To the best of
our knowledge, ours is the first study to report an association between diuretic use and
reduced gait speed, as well as between statin use and increased gait variability in
community-dwelling older adults. We also assessed the associations between
cardiovascular drugs including beta-blockers, alpha-blockers, aspirin and gait
performance.

5.3 Limitations
The studies included in this thesis have a number of limitations. In terms of
generalizability, this thesis focused on community-dwelling older adults so its findings
cannot be generalized to nursing home residents or hospitalized patients. This thesis also
excluded patients with neurological or neurodegenerative diseases that impair mobility.
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Given that the relationship between medication use and falls is a recently emerging topic,
there is no consensus on the drug classes that can be classified as fall risk-increasing.
This has implications for both our systematic review and our cross-sectional study. For
our systematic review, we relied on current guidelines such as the Beers criteria and
previous systematic reviews by the EuGMS Task Force on Falls to inform our search
strategy4,5,6. Studies of gait performance involving drug classes that were not identified as
FRIDs in those resources were not included in our review. In our own study, we assessed
the impact of drug classes such as aspirin, beta-blockers and alpha-blockers, although
there is no consensus on whether those drug classes can be classified as fall riskincreasing due to the inconsistent evidence reported in the literature. We could not
perform a meta-analysis due to the small number of studies for each drug class,
inconsistency in statistical effect measures reported and heterogeneity in gait assessment
protocols.
An important limitation in the observational studies included in our systematic review as
well as our own study is confounding by indication. Studies attempted to minimize this
by adjusting for confounders identified through clinical judgement, the literature and
statistical methods such as bivariate analyses or stepwise regression. For our own study,
we adjusted for known demographic and health-related confounders based on clinical
judgement and a review of the literature. We also adjusted for comorbidities by creating a
comorbidity propensity score for each drug class (based on the comorbidities associated
with both the drug class and the gait performance measure being examined) and
including the propensity score as a covariate in our models. Nonetheless, confounding by
indication and residual confounding cannot be completely eliminated in observational
studies. Other limitations of our study include the cross-sectional design which limits our
ability to establish the temporality of the associations we found. We did not have
information on drug-drug interactions or dosage recorded in our database so we could not
consider the impact of those factors in our study.
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5.4 Future Directions
The findings of this thesis provide several ideas for future research. Broadly, the existing
literature on the association between FRIDs and gait performance in community-dwelling
older adults is relatively limited in contrast to the large body of knowledge on the
association between FRIDs and falls. This was shown in our systematic review which
retrieved a total of 20 studies for both psychotropic and cardiovascular FRIDs. Gait
performance is an important predictor of future health outcomes in older adults including
future falls, cognitive impairment and progression to dementia therefore more research is
needed to expand the knowledge base on the relationship between medication use and
gait. There is a particular need for more research on the association between
cardiovascular FRIDs and gait performance given the high prevalence of cardiovascular
conditions among older adults. Additionally, more research is needed to discern the
impact of FRIDs on gait performance measures other than gait speed such as gait
variability. These measures are important markers of gait performance and provide
information on gait stability.
Given that drug classes are often broad, further research is required to see whether
subclasses of drugs have differential effects on gait performance. For example, we found
an association between diuretic use and reduced gait speed in older adults. Future studies
could look into the potential differential effects of loop diuretics and thiazide diuretics
and gait. This also applies to other drug classes including SSRI and TCA antidepressants
as well as short and long-acting benzodiazepines.
Finally, future research on the relationship between FRID use and gait performance
should be conducted through clinical trials if possible. Clinical trials can eliminate the
risk of bias arising from confounding by indication and residual confounding in
observational studies. They can also help establish the clinical relevance of associations
reported in observational studies.
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5.5 Conclusion
This thesis examined the association between psychotropic and cardiovascular FRIDs and
gait performance in community-dwelling older adults through a systematic review and a
cross-sectional study. Our systematic review found that in the majority of studies
reviewed, the use of drugs with sedative properties was associated with reduced gait
speed in community-dwelling older adults. Our review also identified several knowledge
gaps including the association between cardiovascular drugs and gait performance. We
conducted a cross-sectional study on the association between FRIDs and gait
performance in community-dwelling adults aged 65 years old and over using medication
use data from the Gait and Brain Study. We found statistically significant associations
between diuretic use and reduced gait speed as well as statin use and increased stride time
variability. Further research is required to establish causality and determine the clinical
relevance of those findings. Broadly, the findings of this thesis suggest that, given the
multifactorial nature of falls, caution should be exercised when prescribing drugs with
sedative properties as well as diuretics to older adults at an increased risk of falls. Further
research is required to confirm our finding on the association between statin and
increased stride time variability.
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Appendix 3A: Search Strategy - Psychotropic FRIDs
a) Database search
The following search was run on January 28th, 2020 and updated on June 19th, 2020. A
separate search was run in each of Ovid MEDLINE® (1946 to 2020), Ovid EMBASE
(1947 to 2020), Ovid APA PsycINFO (1806-2020) and EBSCOhost CINAHL (19812020). Every search strategy included database-specific subject headings and a general
keyword search.
MEDLINE
1. exp Gait Analysis/ or exp Gait/ or exp Gait Disorders, Neurologic/
2. limit 1 to (english language and humans)
3. (gait or gait disorder* or gait deficit* or gait impairment* or walk*).ti,ab,tw.
4. limit 3 to (english language and humans)
5. 2 or 4
6. exp "Aged, 80 and over"/ or exp Aged/
7. limit 6 to (english language and humans)
8. (Aged or older adult* or elder*).ti,ab,tw.
9. limit 8 to (english language and humans)
10. exp benzodiazepines/ or exp psychotropic drugs/ or exp antidepressive agents/ or exp
antipsychotic agents/ or exp "hypnotics and sedatives"/ or exp Anticonvulsants/
11. limit 10 to (english language and humans)
12. (psychotropic* or antiepileptic* or neuroleptic* or antidepressant* or
benzodiazepine* or anxiolytic* or hypnotic* or sedative*).ti,ab,tw.
13. limit 12 to (english language and humans)
14. 7 or 9
15. 11 or 13
16. 5 and 14 and 15
Total records uploaded to Mendeley: 473

EMBASE
1. exp Gait Analysis/ or exp Gait/ or exp Gait Disorders, Neurologic/
2. limit 1 to (english language and humans)
3. (gait or gait disorder* or gait deficit* or gait impairment* or walk*).ti,ab,tw.
4. limit 3 to (english language and humans)
5. 2 or 4
6. exp "Aged, 80 and over"/ or exp Aged/
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7. limit 6 to (english language and humans)
8. (Aged or older adult* or elder*).ti,ab,tw.
9. limit 8 to (abstracts and english language and humans)
10. exp benzodiazepines/ or exp psychotropic drugs/ or exp antidepressive agents/ or exp
antipsychotic agents/ or exp hypnotic agent/ or exp sedative agent/ or exp anticonvulsive
agent/
11. limit 10 to (english language and humans)
12. (psychotropic* or antiepileptic* or neuroleptic* or antidepressant* or
benzodiazepine* or anxiolytic* or hypnotic* or sedative*).ti,ab,tw.
13. limit 12 to (english language and humans)
14. 7 or 9
15. 11 or 13
16. 5 and 14 and 15
Total records uploaded to Mendeley: 1904

APA PsycINFO
1. exp Gait/ or exp Motor Processes/ or exp Walking/ or exp Movement Disorders/
2. limit 1 to (human and english language)
3. (gait or gait disorder* or gait deficit* or gait impairment* or walk*).ti,ab,tw.
4. limit 3 to (human and english language)
5. exp Antidepressant Drugs/ or exp Psychopharmacology/ or exp Neuroleptic Drugs/ or
exp Benzodiazepines/ or exp Hypnotic Drugs/ or exp Sedatives/ or exp Anticonvulsive
Drugs/
6. limit 5 to (human and english language)
7. (psychotropic* or antiepileptic* or neuroleptic* or antidepressant* or benzodiazepine*
or anxiolytic* or hypnotic* or sedative*).ti,ab,tw.
8. limit 7 to (human and english language)
9. exp Geriatric Patients/ or exp Aging/ or exp Geriatrics/
10. limit 9 to (human and english language)
11. (Aged or older adult* or elder*).ti,ab,tw.
12. limit 11 to (human and english language)
13. 2 or 4
14. 6 or 8
15. 10 or 12
16. 13 and 14 and 15
Total records uploaded to Mendeley: 795
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CINAHL
S10 S7 AND S8 AND S9
S9
S5 OR S6
S8
S3 OR S4
S7
S1 OR S2
S6
""older adults OR elderly OR seniors OR geriatrics""
Limiters - English
Language; Publication Type: Abstract; Age Groups: Middle Aged: 45-64 years, Aged:
65+ years, Aged, 80 and over; Language: English
S5
(MH "Aged+") OR (MH "Aged, 80 and Over+")
Limiters - English Language;
Human; Age Groups: Middle Aged: 45-64 years, Aged: 65+ years, Aged, 80 and over
S4
""benzodiazepine* OR antidepressant* OR antiepileptic* OR psychotropic* OR
neuroleptic* OR hypnotic* OR sedative*"" Limiters - English Language; Publication
Type: Abstract; Age Groups: Middle Aged: 45-64 years, Aged: 65+ years, Aged, 80 and
over;
S3
(MH "Psychotropic Drugs+") OR (MH "Antidepressive Agents+") OR (MH
"Antianxiety Agents, Benzodiazepine+") OR (MH "Antipsychotic Agents+") OR (MH
"Hypnotics and Sedatives+") OR (MH "Anticonvulsants+") Limiters - English Language;
Age Groups: Middle Aged: 45-64 years, Aged: 65+ years, Aged, 80 and over
S2
""gait OR gait disorder* OR gait deficit* OR gait impairment* OR OR walk*""
Limiters - Human; Publication Type: Abstract; Age Groups: Middle Aged: 45-64
years, Aged: 65+ years, Aged, 80 and over; Language: English
S1
(MH "Gait+") OR (MH "Gait Disorders, Neurologic+") OR (MH "Gait Analysis")
OR (MM "Walking Speed") Limiters - Human; Age Groups: Middle Aged: 45-64 years,
Aged: 65+ years, Aged, 80 and over; Language: English
Total records uploaded to Mendeley: 13

b) Grey Literature search
WEB OF SCIENCE
(TS=(gait or gait disorder* or gait deficit* or gait impairment* or
walk*) .) AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article)
AND
(TS=(psychotropic* or antiepileptic* or neuroleptic* or antidepressant* or
benzodiazepine* or anxiolytic* or hypnotic* or
sedative*) .) AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article)
AND
(TS=(Aged or older adult* or
elder*) ) AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article)
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Total records uploaded to Mendeley: 2
PROQUEST DISSERTATIONS & THESIS GLOBAL
ab(gait OR gait disorder* OR gait deficit* OR gait impairment* OR walk*) AND
ab(psychotropic* or antiepileptic* or neuroleptic* or antidepressant* or benzodiazepine*
or anxiolytic* or hypnotic* or sedative*) AND ab(Aged or older adult* or elder*)
Total records uploaded to Mendeley: 0

Appendix 3B: Search Strategy - Cardiovascular FRIDs
a) Database search
The following search was run on June 15th, 2020. A separate search was run in each of
Ovid MEDLINE® (1946 to 2020), Ovid EMBASE (1947 to 2020), Ovid APA PsycINFO
(1806-2020) and EBSCOhost CINAHL (1981-2020). Every search strategy included
database-specific subject headings and a general keyword search.
MEDLINE
1. exp Gait Analysis/ or exp Gait/ or exp Gait Disorders, Neurologic/
2. limit 1 to (english language and humans)
3. (gait or gait disorder* or gait deficit* or gait impairment* or walk*).ti,ab,tw.
4. limit 3 to (english language and humans)
5. exp Diuretics/
6. limit 5 to (english language and humans)
7. exp Vasodilator Agents/
8. limit 7 to (english language and humans)
9. exp Adrenergic beta-Antagonists/
10. limit 9 to (english language and humans)
11. exp Adrenergic alpha-Antagonists/
12. limit 11 to (english language and humans)
13. exp Calcium Channel Blockers/
14. limit 13 to (english language and humans)
15. exp Angiotensin-Converting Enzyme Inhibitors/
16. limit 15 to (english language and humans)
17. exp Angiotensin II Type 1 Receptor Blockers/
18. limit 17 to (english language and humans)
19. exp Antihypertensive Agents/
20. limit 19 to (english language and humans)
21. exp Hydroxymethylglutaryl-CoA Reductase Inhibitors/
22. limit 21 to (english language and humans)
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23. exp cardiac glycosides/
24. limit 23 to (english language and humans)
25. exp Cardiovascular Agents/
26. limit 25 to (english language and humans)
27. exp "Aged, 80 and over"/ or exp Aged/
28. limit 27 to (english language and humans)
29. (Aged or older adult* or elder*).ti,ab,tw.
30. limit 29 to (english language and humans)
31. (diuretic* or vasodilator agent* or antihypertensive agent* or Adrenergic betaAntagonist* or beta blocker* or Alpha-adrenoceptor antagonist* or alpha blocker* or
ACE inhibitor* or angiotensin II inhibitor* or Hydroxymethylglutaryl-CoA Reductase
Inhibitor* or statin* or calcium antagonist* or calcium channel blocker* or cardiac
glycoside* or cardiovascular agent*).ti,ab,tw.
32. limit 31 to (english language and humans)
33. 2 or 4
34. 6 or 8 or 10 or 12 or 14 or 16 or 18 or 20 or 22 or 24 or 26 or 32
35. 28 or 30
36. 33 and 34 and 35
Total records uploaded to Mendeley: 1608

EMBASE
1. exp Gait Analysis/ or exp Gait/ or exp Gait Disorders, Neurologic/
2. limit 1 to (human and english language)
3. (gait or gait disorder* or gait deficit* or gait impairment* or walk*).ti,ab,tw.
4. limit 3 to (human and english language)
5. exp diuretic agent/
6. limit 5 to (human and english language)
7. exp vasodilator agent/
8. limit 7 to (human and english language)
9. exp alpha adrenergic receptor blocking agent/
10. limit 9 to (human and english language)
11. exp beta adrenergic receptor blocking agent/
12. limit 11 to (human and english language)
13. exp calcium channel blocking agent/
14. limit 13 to (human and english language)
15. exp calcium antagonist/
16. limit 15 to (human and english language)
17. exp dipeptidyl carboxypeptidase inhibitor/
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18. limit 17 to (human and english language)
19. exp angiotensin II antagonist/
20. limit 19 to (human and english language)
21. exp hydroxymethylglutaryl coenzyme A reductase inhibitor/
22. limit 21 to (human and english language)
23. exp cardiovascular agent/
24. limit 23 to (human and english language)
25. exp antihypertensive agent/
26. limit 25 to (human and english language)
27. exp cardiac glycoside/
28. limit 27 to (human and english language)
29. (diuretic* or vasodilator agent* or antihypertensive agent* or Adrenergic betaAntagonist* or beta blocker* or Alpha-adrenoceptor antagonist* or alpha blocker* or
ACE inhibitor* or angiotensin II inhibitor* or Hydroxymethylglutaryl-CoA Reductase
Inhibitor* or statin* or calcium antagonist* or calcium channel blocker* or cardiac
glycoside* or cardiovascular agent*).ti,ab,tw.
30. limit 29 to (human and english language)
31. exp "Aged, 80 and over"/ or exp Aged/
32. limit 31 to (human and english language)
33. (Aged or older adult* or elder*).ti,ab,tw.
34. limit 33 to (human and english language)
35. 2 or 4
36. 6 or 8 or 10 or 12 or 14 or 16 or 18 or 20 or 22 or 24 or 26 or 28 or 30
37. 32 or 34
38. 35 and 36 and 37
Total records uploaded to Mendeley: 3301

APA PsycINFO
1. exp Gait/ or exp Motor Processes/ or exp Walking/ or exp Movement Disorders/
2. limit 1 to (human and english language)
3. exp Vasodilator Drugs/
4. limit 3 to (human and english language)
5. exp Antihypertensive Drugs/
6. limit 5 to (human and english language)
7. exp Adrenergic Blocking Drugs/
8. limit 7 to (human and english language)
9. exp Channel Blockers/
10. limit 9 to (human and english language)

82

11. exp Statins/
12. limit 11 to (human and english language)
13. exp digoxin/
14. limit 13 to (human and english language)
15. exp "Side Effects (Drug)"/
16. limit 15 to (human and english language)
17. (diuretic* or vasodilator agent* or antihypertensive agent* or Adrenergic betaAntagonist* or beta blocker* or Alpha-adrenoceptor antagonist* or alpha blocker* or
ACE inhibitor* or angiotensin II inhibitor* or Hydroxymethylglutaryl-CoA Reductase
Inhibitor* or statin* or calcium antagonist* or calcium channel blocker* or cardiac
glycoside* or cardiovascular agent*).ti,ab,tw.
18. limit 17 to (human and english language)
19. exp Geriatric Patients/ or exp Aging/ or exp Geriatrics/
20. limit 19 to (human and english language)
21. (Aged or older adult* or elder*).ti,ab,tw.
22. limit 21 to (human and english language)
23. (gait or gait disorder* or gait deficit* or gait impairment* or walk*).ti,ab,tw.
24. limit 23 to (human and english language)
25. 2 or 24
26. 4 or 6 or 8 or 10 or 12 or 14 or 16 or 18
27. 20 or 22
28. 25 and 26 and 27
Total records uploaded to Mendeley: 391

CINAHL
S15 S12 AND S13 AND S14
S14 S10 OR S11
S13 S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9
S12 S1 OR S2
S11 "Aged" OR "older adult*" OR "elder*"
Limiters - English Language; Human
S10 (MH "Aged+") OR (MH "Aged, 80 and Over+")
Limiters - English Language;
Human
S9
"diuretic*" OR "vasodilator agent*" OR "antihypertensive agent*" OR
"Adrenergic beta-Antagonist*" OR "beta blocker*" OR "Alpha-adrenoceptor
antagonist*" OR "alpha blocker*" OR "ACE inhibitor*" OR "angiotensin II inhibitor*"
OR "Hydroxymethylglutaryl-CoA Reductase Inhibitor*" OR "statin*" OR "calcium
antagonist*" OR "calcium channel blocker*" OR "cardiac glycoside*" OR
"cardiovascular agent*"
Limiters - English Language; Human
S8
(MH "Statins+")
Limiters - English Language; Human
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S7
(MH "Cardiac Glycosides+") Limiters - English Language; Human
S6
(MH "Angiotensin-Converting Enzyme Inhibitors+") OR (MH "Angiotensin II
Type I Receptor Blockers+") Limiters - English Language; Human
S5
(MH "Adrenergic Alpha-Antagonists+") OR (MH "Adrenergic BetaAntagonists+") OR
(MH "Calcium Channel Blockers+") Limiters - English Language; Human
S4
(MH "Vasodilator Agents+") Limiters - English Language; Human
S3
(MH "Diuretics+") OR (MH "Diuretics, Thiazide+") Limiters - English
Language; Human
S2
"gait" OR "gait disorder*" OR "gait deficit*" OR "gait impairment*" OR "walk*"
Limiters - English Language; Human
S1
(MH "Gait+") OR (MH "Gait Disorders, Neurologic+") OR (MH "Gait Analysis")
OR (MM "Walking Speed") Limiters - English Language; Human
Total records uploaded to Mendeley: 262
b) Grey Literature search
WEB OF SCIENCE
(TS=(gait or gait disorder* or gait deficit* or gait impairment* or
walk*) .) AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article)
AND
(TS=(diuretic* or vasodilator agent* or antihypertensive agent* or Adrenergic betaAntagonist* or beta blocker* or Alpha-adrenoceptor antagonist* or alpha blocker* or
ACE inhibitor* or angiotensin II inhibitor* or Hydroxymethylglutaryl-CoA Reductase
Inhibitor* or statin* or calcium antagonist* or calcium channel blocker* or cardiac
glycoside* or cardiovascular
agent*) ) AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article)
AND
(TS=(Aged or older adult* or
elder*) ) AND LANGUAGE: (English) AND DOCUMENT TYPES: (Article)
Total records uploaded to Mendeley: 6

PROQUEST DISSERTATIONS & THESIS GLOBAL
ab(gait or gait disorder* or gait deficit* or gait impairment* or walk*) AND ab(diuretic*
or vasodilator agent* or antihypertensive agent* or Adrenergic beta-Antagonist* or beta
blocker* or Alpha-adrenoceptor antagonist* or alpha blocker* or ACE inhibitor* or
angiotensin II inhibitor* or Hydroxymethylglutaryl-CoA Reductase Inhibitor* or statin*
or calcium antagonist* or calcium channel blocker* or cardiac glycoside*r cardiovascular
agent*) AND ab(Aged or older adult* or elder*)
Total records uploaded to Mendeley: 0
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Appendix 3C: The Newcastle-Ottawa Scale for quality assessment of cohort and crosssectional studies. The scale was adjusted to fit the review topic

Criteria

Acceptable (* awarded)

Unacceptable (* not
awarded)

Selection
•
1) Representativeness of
the exposed cohort
•

•
2) Selection of the non
exposed cohort

•
3) Ascertainment of
exposure
•

4) Demonstration that
outcome of interest was
not present at start of
study

•

Truly representative of
the average older
persons in the
community *
Somewhat
representative of the
average older persons
in the community *
Drawn from the same
community as the
exposed cohort *

•

Medication
ascertained through
secure records*
Medication
ascertained through
interviews*
Yes*

•

Controlled for age and
other factors* *
Controlled for age
only *

•

•
•

Selected group of
users (e.g. nurses,
volunteers)
No description of
the derivation of the
cohort

Drawn from a
different source
No description of
the derivation of the
non-exposed cohort

•

Medication
ascertained through
self-reports
No description

•

No

•

No description

Comparability
1) Comparability of
cohorts on the basis of
the design or analysis

•
•
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Outcome
1) Assessment of
outcome

•

Independent gait
assessment *
Gait parameters in
medical record *

•
•

Self-report
(retrospective)
No description

•

Yes*

•

No

•

Complete follow-up –
all subjects accounted
for *
Subjects loss to
follow-up unlikely to
introduce bias – small
number lost to followup *

•

Subjects lost to
follow-up likely to
introduce bias
No statement

•

2) Was follow-up long
enough for outcomes to
occur
(N/A for cross-sectional
studies)

3) Adequacy of follow up
of cohorts
(N/A for cross-sectional
studies)

•

•
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Appendix 3D: Quality assessment for observational studies included using the Newcastle-Ottawa scale (NOS) (Psychotropic
FRIDs)
Author (Year
Selection
Comparability
Outcome
Total
of
Score
1)
2)
3)
4)
1)
1)
2) Was follow- 3)
Publication)
(/9)
Representative Selection
Ascertainment Demonstration Comparability Assessment up long enough Adequacy
-ness of the
of nonof exposure
that outcome of cohorts on of outcome for outcomes
of follow
exposed cohort exposed
(*)
of interest was the basis of the (*)
to occur (*)
up of
(*)
not present at design or
(N/A for cross- cohorts (*)
cohort (⋆)
start of study analysis (**)
sectional
(N/A for
(*)
studies)
crosssectional
studies)
Donoghue et
al (2015)

*

*

-

-

**

*

N/A

N/A

5

Poujol et al
(2010)

-

*

-

-

**

*

N/A

N/A

4

Eto et al
(1998)

*

*

-

-

-

*

N/A

N/A

3

Gray et al
(2003)

*

*

*

-

**

*

*

*

8

Landi et al
(2007)

*

*

*

-

**

*

N/A

N/A

6

Cao et al
(2008)

*

*

*

-

**

*

N/A

N/A

6
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Gnijdic et al
(2009)

*

*

*

-

**

*

N/A

N/A

6

Hilmer et al
(2009)

*

*

*

-

**

*

*

*

8

Taipale et al
(2012)

*

*

*

-

**

*

N/A

N/A

6

Lim et al
(2019)

*

*

-

-

**

*

N/A

N/A

5
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Appendix 3E: Quality assessment for observational studies included using the Newcastle-Ottawa scale (NOS) (Cardiovascular
FRIDs)
Author (Year
of
1)
Publication)
Representative
-ness of the
exposed
cohort (*)

Selection

Comparability

2)
Selection
of nonexposed
cohort (⋆)

3)
Ascertainment
of exposure
(*)

4)
Demonstration
that outcome
of interest was
not present at
start of study
(*)

1)
Comparability
of cohorts on
the basis of
the design or
analysis (**)

Outcome
1)
Assessment
of outcome
(*)

2) Was
follow-up
long
enough for
outcomes
to occur (*)
(N/A for
crosssectional
studies)

3)
Adequacy
of follow
up of
cohorts
(*) (N/A
for crosssectional
studies)

Total
Score
(/9)

Onder at al
(2002)

*

*

*

-

**

*

*

*

8

Gray et al
(2012)

*

*

*

-

**

*

*

*

8

George and
Verghese
(2016)

*

*

*

-

**

*

N/A

N/A

6

Dumurgier et *
al (2013)

*

*

*

**

*

*

*

9

Lo-Ciganic
(2014)

*

*

*

**

*

*

*

9

*
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Kawai et al
(2018)

*

*

*

-

**

*

N/A

N/A

6

Deugchi et al
(2019)

*

*

*

*

**

*

N/A

N/A

7

Appendix 3F: Risk of bias assessment for clinical trials included using the Cochrane risk-of-bias tool
Author (Year of
Publication)

Risk of bias domains
Sequence
generation

Allocation
concealment

Blinding

Incomplete
outcome data

Selective
outcome
reporting

Other potential
threats to
validity

Summary
bias

Draganich et al
(2001)

Low

Low

Low

Low

Low

Low

Low risk

Paleacau et al
(2007)

High

High

High

Low

Low

Low

High risk

Cesari et al

Unclear

Unclear

Low

Low

Low

Low

Unclear risk

(2009)
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Appendix 4A: Comorbidity propensity score models for the association between FRIDs and Gait Speed

1) SSRI

91

2) Benzodiazepine

92

3) Alpha-blockers

93

4) Beta-blockers

94

5) Vasodilators

95

6) Statin

96

7) Aspirin

97

8) Diuretics
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Appendix 4B: Comorbidity propensity score models for the association between FRIDs and Stride Time Variability
(Stride Time CV)

1) SSRI

99

2) Benzodiazepines

100

3) Alpha-blockers

101

4) Beta-blockers

102

5) Vasodilators

103

6) Statin

104

7) Aspirin

105

8) Diuretics
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Appendix 4C: Sensitivity analysis results.
1) The Associations between FRID Use and Gait Speed
Complete Case Analysis
MICE Imputed Data
(n=319)
(n=345)
Drug class
Regression
P-value
Drug class
Regression
P-value
coefficient*
coefficient*
Antidepressants -1.90
0.582
Antidepressants -3.16
0.368
Benzodiazepines -1.29
0.776
Benzodiazepines 1.26
0.776
Diuretics
-7.97
0.009
Diuretics
-6.22
0.041
Statin
-1.47
0.546
Statin
-2.56
0.293
Vasodilators
4.83
0.082
Vasodilator
4.84
0.084
Alpha-blockers
-6.20
0.147
Alpha-blockers
-3.90
0.348
Beta-blockers
-3.13
0.328
Beta-blockers
-3.54
0.276
Aspirin
-0.14
0.954
Aspirin
-0.44
0.858
2) The Associations between FRID Use and Stride Time Variability (Stride Time CV)
Complete Case Analysis
(n=319)
Drug class
Regression
P-value
coefficient*
Antidepressants 0.01
0.905
Benzodiazepines 0.12
0.270
Diuretics
-0.05
0.515
Statin
0.13
0.026
Vasodilators
-0.05
0.491
Alpha-blockers
0.15
0.144
Beta-blockers
0.09
0.209
Aspirin
-0.01
0.898

MICE Imputed Data
(n=345)
Drug class
Regression
P-value
coefficient*
Antidepressants 0.05
0.570
Benzodiazepines 0.02
0.825
Diuretics
-0.04
0.606
Statin
0.12
0.044
Vasodilator
-0.05
0.438
Alpha-blockers
0.13
0.178
Beta-blockers
0.07
0.364
Aspirin
-0.03
0.959

* Regression coefficients after adjusting for covariates
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